alpha-aminopyridine has been researched along with carbostyril in 293 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (2.05) | 29.6817 |
| 2010's | 194 (66.21) | 24.3611 |
| 2020's | 93 (31.74) | 2.80 |
| Authors | Studies |
|---|---|
| Booker, GW; Branson, KM; Cawthray, JF; Fritz, D; Inglis, SR; Pyke, SM; Stojkoski, C; Wiadrowski, E | 1 |
| Bach, A; Bucciarelli, S; Gotfredsen, CH; Høj, LJ; Langkilde, AE; Meier, S; Narayanan, D; Sattler, M; Softley, C; Solbak, SMØ; Zang, J | 1 |
| Akaki, T; Kajitani, H; Sato, K; Shishido, S; Tomioka, H | 1 |
| Cosi, C; Newman-Tancredi, A; Rollet, K; Tesori, V; Waget, A | 1 |
| Inaba, T; Shishikura, T; Shito, K; Uchida, M | 1 |
| Hirata, T; Hoshino, K; Okumura, R; Onodera, Y; Otani, T; Yamamoto, T | 1 |
| Retsch-Bogart, GZ | 1 |
| Gillissen, A; Häussermann, A | 1 |
| Goto, K; Jindo, T; Sanbuissho, A; Suzuki, T; Yabe, K | 1 |
| Rochat, T | 1 |
| Chazan, RC | 1 |
| Salmon, M; Tannheimer, SL; Wright, CD | 1 |
| Lundquist, LM; Metzger, NL | 1 |
| Bertoncini, E; Colomb-Lippa, D | 1 |
| Fox, JL | 1 |
| Galietta, LJ | 1 |
| Rowe, SM; Verkman, AS | 1 |
| Cantón, R; Espinal, P; Garcia-Alonso, F; Gargallo-Viola, D; López, Y; Tato, M; Vila, J | 2 |
| Bolger, GB; Coricor, GE; Courville, CA; Dransfield, MT; Farris, RF; Lambert, JA; Li, Y; Mazur, MM; McNicholas, CM; Raju, SV; Rowe, SM; Smoot, LH; Tang, LP | 1 |
| Durieu, I; Durupt, S; Nove Josserand, R | 1 |
| Cantón, R; Garcia-Alonso, F; Gargallo-Viola, D; López, Y; Moreno-Bofarull, A; Morosini, MI; Tato, M; Vila, J | 1 |
| Doe, SJ; Lane, MA | 1 |
| Baroni, D; Moran, O; Svensson, A; Zegarra-Moran, O | 1 |
| Bompadre, SG; Kopeikin, Z; Yang, HY; Yuksek, Z | 1 |
| Tümmler, B | 2 |
| Bell, SC; Boyle, MP; Huang, X; Konstan, MW; McColley, SA; Patel, NR; Rietschel, E; Rodman, D; Rowe, SM; Waltz, D | 1 |
| Chen, JH | 1 |
| Gropper, S | 1 |
| Albareda, N; Febbraro, S; Gropper, S; Santos, B | 2 |
| Cepero, AL; Dosik, JS; Gropper, S; LaStella, P; Siemetzki, H; Wigger-Alberti, W | 1 |
| Gropper, S; Ortiz, J; Santos, B | 1 |
| Cepero, AL; Gropper, S; Kruger, D; Santos, B | 1 |
| Albareda, N; Chelius, K; Gani, M; García-Alonso, F; Gropper, S; Kruger, D; Mitha, I; Vahed, Y | 1 |
| Kumar, S; Shankar, A; Tana, A | 1 |
| Eldredge, LC; Ramsey, BW | 1 |
| Ma, T; Yang, H | 1 |
| Davis, PB | 1 |
| Boyle, MP; Cipolli, M; Colombo, C; Davies, JC; De Boeck, K; Elborn, JS; Flume, PA; Huang, X; Konstan, MW; Marigowda, G; McColley, SA; McCoy, K; McKone, EF; Munck, A; Ramsey, BW; Ratjen, F; Rowe, SM; Wainwright, CE; Waltz, D | 1 |
| Mayor, S | 1 |
| Akkermans, R | 1 |
| Barry, PJ; Jones, AM | 1 |
| Marshall, SG; Ramsey, BW; Rowe, SM; Solomon, GM | 1 |
| Bilton, D | 1 |
| Nau, JY | 1 |
| Ferkol, T; Quinton, P | 1 |
| Carlier, J; Kupchick, T; Larder, A; McCarty, J; Powers, M; Thomas, J; Virant-Young, D; Woiderski, S | 1 |
| Ong, T; Ramsey, BW | 2 |
| Silverman, E | 1 |
| Brodsky, JL; Frizzell, RA | 1 |
| Kuk, K; Taylor-Cousar, JL | 1 |
| Billet, A; Carlile, GW; Dejgaard, K; Goepp, J; Hanrahan, JW; Luo, Y; Matthes, E; Robert, R; Thomas, DY | 1 |
| Boyle, M; Elborn, JS; Ramsey, B; Wainwright, C | 1 |
| Elborn, JS; Ramsey, BW; Wainwright, CE | 1 |
| Baloch, NU; Janahi, IA; Rehman, A | 1 |
| Azvolinsky, A | 1 |
| Calverley, P; Celli, BR; Chambers, M; Clark, JF; Hawkins, N; Scott, DA; Thompson, JC; Woods, B | 1 |
| Brewington, JJ; Clancy, JP; McPhail, GL | 1 |
| Bridgeman, MB; Dalal, KS | 1 |
| Mayer, M | 1 |
| Bui, S; Colomb-Jung, V; Corvol, H; Hubert, D; Marguet, C; Munck, A; Murris-Espin, M | 1 |
| Boyle, M; Mayer-Hamblett, N; VanDevanter, D | 1 |
| Reinhardt, D | 1 |
| Desch, M | 1 |
| Quon, BS; Rowe, SM | 1 |
| Amano, A; Ikeda, F; Ishii, R; Kanayama, S; Matsumoto, S; Matsumoto, T; Matsuzaki, K; Nakajima, A; Okamoto, K | 1 |
| Bali, V; Bebok, Z; Guroji, P; Lazrak, A; Matalon, S | 1 |
| Naren, AP; Strokes, DC; Zhang, W; Zhang, X; Zhang, YH | 1 |
| Boyle, MP; Elborn, JS; Huang, X; Konstan, MW; Marigowda, G; Ramsey, BW; Wainwright, CE; Waltz, D | 1 |
| Fujikawa, A; Ikeda, F; Ishii, R; Kanayama, S; Kawashima, M; Matsumoto, T; Nakajima, A; Okamoto, K; Takei, K | 1 |
| Meißner, T | 1 |
| Gulland, A | 1 |
| Beekman, JM; Berkers, G; Bronsveld, I; Clevers, H; de Jonge, HR; de Rijke, YB; de Winter-de Groot, KM; Dekkers, JF; Escher, JC; Heijerman, HG; Houwen, RH; Janssens, HM; Kruisselbrink, E; Majoor, CJ; Nieuwenhuis, EE; van de Graaf, EA; van der Ent, CK; Vleggaar, FP; Vonk, A | 1 |
| Deeks, ED | 1 |
| Chaudhry, IG; Cholon, DM; Cyr, DM; Das, J; Dokholyan, NV; Gentzsch, M; Houck, SA; Quinney, NL; Randell, SH; Ren, HY; Sopha, P | 1 |
| Kikukawa, Y; Morimoto, H; Murakami, N | 1 |
| Azad, MA; Baker, MA; Bergen, PJ; Cooper, MA; Doi, Y; Han, ML; Huang, JX; Li, J; Muller, MT; Schneider, EK; Tony Zhou, Q; Velkov, T; Wang, J | 1 |
| Cogen, J; Goss, CH; Heltshe, SL; Ramos, KJ | 1 |
| Keating, D; Kotsimbos, T; Li, J; Reyes-Ortega, F; Schneider, EK; Velkov, T; Wilson, JW | 1 |
| Li, J; Reyes-Ortega, F; Schneider, EK; Velkov, T | 2 |
| Bankovic, J; Dragoj, M; Milosevic, Z; Pesic, M; Stankovic, T; Tanic, N | 1 |
| Goss, CH; Huang, X; Konstan, MW; Lubarsky, B; Marigowda, G; Mayer-Hamblett, N; McKone, EF; Millar, SJ; Morgan, W; Moss, RB; Pasta, DJ; Rubin, J; Sawicki, GS; Tian, S; Waltz, D | 1 |
| Cai, Z; Ford, RC; Li, H; Meng, X; Rimington, TL; Sheppard, DN; Wang, X; Wang, Y; Wrennall, JA | 1 |
| Aitken, ML; Godfrey, EM; Heltshe, SL; Josephy, T; Taylor-Cousar, JL | 1 |
| Casey, A; Chmiel, JF; Donaldson, SH; Flume, PA; Mandagere, A; McCoy, K; Shoemaker, SA; Solomon, GM; Taylor-Cousar, JL; Troha, JM; Zeitlin, PL; Zemanick, ET | 1 |
| Egan, ME | 1 |
| Gotoh, N; Hayashi, N; Ikeda, F; Ishii, R; Kanayama, S; Matsumoto, T; Okamoto, K | 1 |
| Braun, A; Dezube, R; Grant, J; Hong, G; Jennings, MT; Lechtzin, N; Merlo, CA; Paranjape, S; West, NE | 1 |
| Barry, P; Horsley, A | 1 |
| Ramsey, BW; Welsh, MJ | 1 |
| Goralski, JL; McKinzie, CJ; Noah, TL; Prieur, MB; Retsch-Bogart, GZ | 1 |
| Mayer-Hamblett, N; VanDevanter, DR | 1 |
| Casciaro, R; Costa, S; Dang, P; Majo, F; Ros, M | 1 |
| Houwen, RHJ; Slae, M; van der Woerd, WL; Wilschanski, M | 1 |
| Amenduni, M; Fabris, L; Fiorotto, R; Mariotti, V; Spirli, C; Strazzabosco, M | 1 |
| Bertolini, A; Bodewes, FAJA; Jonker, JW; van de Peppel, IP; Verkade, HJ | 1 |
| McColley, SA; Talamo Guevara, M | 1 |
| Davies, J; Elborn, JS | 1 |
| Bulloch, MN; Giovane, R; Hanna, C | 1 |
| AbuArish, A; Cantin, AM; Cloutier, A; Cosa, G; Greene, LE; Hanrahan, JW; Matthes, E; Robert, R; Thomas, DY; Turner, MJ; Wong, FH | 1 |
| Ashare, A; Barnaby, R; Berwin, B; Hampton, TH; Koeppen, K; Nymon, A; Stanton, BA | 1 |
| Aban, I; Boyles, SE; Chaudhry, IG; Chua, M; Gentzsch, M; Guimbellot, JS; Jaspers, I; Leach, JM; Quinney, NL | 1 |
| Cutting, GR | 1 |
| Amer, AO; Badr, A; Caution, K; Cormet-Boyaka, E; Dakhlallah, D; Hall-Stoodley, L; Hamilton, K; Hayes, D; Kirkby, SE; Klamer, BG; Kopp, BT; Krause, K; McCoy, KS; Parinandi, NL; Partida-Sanchez, S; Robledo-Avila, F; Shrestha, C; Tazi, MF; Tumin, D; Zhang, X | 1 |
| Campbell, JD; Dilokthornsakul, P; Patidar, M | 1 |
| DiMango, E; Hopkins, BD; Kitur, K; Parsons, R; Prince, A; Riquelme, SA; Wolfe, AL | 1 |
| Alejandre Alcazar, MA; Mueller, MI; Rietschel, E; Thomassen, JC; van Koningsbruggen-Rietschel, S | 1 |
| Baatallah, N; Bitam, S; Callebaut, I; Chevalier, B; Costes, B; Edelman, A; Fanen, P; Girodon, E; Hinzpeter, A; Hoffmann, B; Martin, N; Mekki, C; Mornon, JP; Pranke, I; Sermet-Gaudelus, I; Servel, N; Simonin, J | 1 |
| Bagheri-Hanson, A; Dopfer, C; Dorda, M; Fischer, S; Graeber, SY; Gyulumyan, L; Hirtz, S; Hyde, R; Mairbäurl, H; Mall, MA; Naehrlich, L; Rueckes-Nilges, C; Scheuermann, H; Tümmler, B; Wege, S | 1 |
| Brochiero, E; Maillé, É; Rousseau, S; Roussel, L; Ruffin, M | 1 |
| Bell, SC; Wood, ME | 1 |
| Benden, C; Bürgi, U; Hirt, A; Huber, LC; Kurowski, T; Murer, C; Robinson, CA | 1 |
| Hayes, D; Kopp, BT; McCulloch, S; Sarzynski, L; Shrestha, CL; Woodley, FW; Zhang, S | 1 |
| Backstrom, J; Brewington, JJ; Clancy, JP; Feldman, A; Kramer, EL; Lu, LJ; Moncivaiz, JD; Ostmann, AJ; Zhu, X | 1 |
| Burgener, EB; Moss, RB | 1 |
| Brewington, JJ; Clancy, JP; Harkness, B; McCarthy, C; Trapnell, BC | 1 |
| Schneider, EK | 1 |
| Doull, I | 2 |
| Adam, D; Bilodeau, C; Brochiero, E; Maillé, É; Ruffin, M; Sognigbé, L | 1 |
| Avolio, J; Bartlett, C; Bear, CE; Du, K; Eckford, PDW; Gonska, T; He, G; Ho, K; Huan, LJ; Jiang, JX; Klingel, M; Kyriakopoulou, L; McCormack, J; Moraes, TJ; Munsie, L; Ouyang, H; Pereira, SL; Ratjen, F; Rossant, J; Stanojevic, S; Strug, LJ; Wellhauser, L; Wong, AP; Yang, JY | 1 |
| Aftab, B; Amir, N; Fayyaz, A; Hanif, M; Ijaz, H; Mustafa, MI; Qureshi, J; Rasul, A | 1 |
| Bruch, BA; Ramsey, LJ; Singh, SB; Starner, TD | 1 |
| Mishra, AK; Sahu, JK | 1 |
| Awori, MS; Blazquez, T; Chouinard, L; Gargallo-Viola, D; González Borroto, JI; Smith, SY; Tarragó, C; Zsolt, I | 1 |
| Arañó, A; D'Aniello, F; Esquirol, LP; Lachamp, L; Tarragó, C; Zsolt, I | 1 |
| Canton, R; Chouinard, L; Tarragó, C | 1 |
| Canton, R; García-Castillo, M; Gargallo-Viola, D; López, Y; Morrissey, I; Tato, M; Vila, J; Zsolt, I | 1 |
| Gentzsch, M; Mall, MA | 1 |
| Flume, PA; Jennings, MT | 1 |
| Esther, CR; McKinzie, C; Stringer, E; Terrell, M; Trimble, A | 1 |
| Albareda, N; Alonso, FG; Hebert, AA; Rosen, T; Rosenberg, N; Roth, S; Zsolt, I | 1 |
| Ahmadi, S; Bear, CE; Chin, S; Elmallah, S; Hamilton, CM; Hung, M; Toutah, K; Viirre, RD; Won, A; Wu, YS; Yang, D; Yip, CM; Young, RN | 1 |
| Connett, GJ; Hammond, JA | 1 |
| Bell, E; Eiland, LS; Wren, C | 1 |
| Cai, Z; Cutting, GR; Davis, EF; Evans, TA; Han, ST; Hong, JS; Joynt, AT; Lu, Z; McCague, AF; Pellicore, MJ; Rab, A; Raraigh, KS; Sheppard, DN; Sorscher, EJ | 1 |
| Nevitt, SJ; Patel, S; Sinha, IP; Southern, KW | 2 |
| Jain, M; Sala, MA | 2 |
| Chan, CL; Li, A; Nadeau, K; Pyle, L; Sagel, SD; Vigers, T; Zemanick, E | 1 |
| Crawford, KJ; Downey, DG | 1 |
| Boyle, MP; Jiang, JG; Konstan, MW; Marigowda, G; McColley, SA; Ramsey, BW; Rubin, JL; Stuart Elborn, J; Vera-Llonch, M; Wainwright, CE; Waltz, D | 1 |
| Barry, PJ; Jones, AM; Mitchell, RM | 1 |
| Amaral, MD; Barros, P; Faria, M; Gomes-Duarte, A; Jordan, P; Matos, AM; Matos, P | 1 |
| Fink, AK; Loeffler, DR; Mayer-Hamblett, N; Sawicki, GS; Schechter, MS | 1 |
| Kissner, D; Le Camus, C; LeFlore, Y; Marigowda, G; Narayan, SB; Simard, C | 1 |
| Covvey, JR; Giannetti, V; Kamal, KM; Mukherjee, K; Vadagam, P | 1 |
| Caskey, RN; Dowell, ML; Hung, YT; Sharma, D; Touchette, DR; Xing, S | 1 |
| Boyles, SE; Cholon, DM; Gentzsch, M; Martino, MEB; Quinney, NL; Ribeiro, CMP | 1 |
| Bonk, MP; Hadjiliadis, D; Rey, MM | 1 |
| Albareda, N; Grimalt, R; Hebert, AA; Masramon, X; Rosen, T; Rosenberg, N; Torrelo, A; Zsolt, I | 1 |
| Hwang, TC; Yeh, JT; Yu, YC | 1 |
| Kopp, BT; Shrestha, CL; Zhang, S | 1 |
| Barrio, M; Blanco-Aparicio, M; Cols-I-Roig, M; Delgado-Pecellín, I; Diab-Cáceres, L; Fernández, O; García-Clemente, MM; Girón-Moreno, RM; Gómez-de-Terreros-Caro, FJ; González, M; López-Neyra, A; Luna-Paredes, C; Maiz, L; Mondéjar-López, P; Palou-Rotger, A; Pastor-Sanz, MT; Quintana-Gallego, E; Ruiz-de-Valbuena, M | 1 |
| Bratcher, PE; Nichols, DP; Nick, JA; Pohl, K; Saavedra, MT; Strand, MJ; Taylor-Cousar, JL | 1 |
| Cheng, DY; Wei, J; Wu, HX; Xiong, XF; Zhu, M; Zhuo, KQ | 1 |
| Flume, PA; Kosinski, M; Marigowda, G; Quittner, AL; Suthoff, ED | 1 |
| Achimastos, D; Baatallah, N; Bailly, C; Chedevergne, F; Edelman, A; Flament, T; Girodon, E; Hatton, A; Hinzpeter, A; Kyrilli, S; Le Bourgeois, M; Masson, A; Nguyen-Khoa, T; Schneider-Futschik, EK; Sermet-Gaudelus, I | 1 |
| Beekman, JM; Braakman, I; de Jonge, HR; Egmond, MR; Kleizen, B; Kruisselbrink, E; van der Ent, CK; van der Sluijs, P; van Willigen, M; Vonk, AM; Yeoh, HY | 1 |
| Hussar, DA | 1 |
| Garbuzenko, OB; Kbah, N; Kuzmov, A; Minko, T; Pogrebnyak, N; Pozharov, V | 1 |
| Cantón, R; García-Castillo, M; Hebert, AA; López, Y; Tato, M; Torrelo, A; Vila, J | 1 |
| Flume, PA | 1 |
| Li, C; Liu, F; Marigowda, G; McColley, SA; McNamara, JJ; Owen, CA; Sawicki, GS; Stiles, D; Tian, S; Waltz, D; Wang, LT | 1 |
| Amaral, MD; Bertuzzo, CS; Kmit, A; Leite, GS; Marson, FAL; Pereira, SV; Ribeiro, AF; Ribeiro, JD; Servidoni, MF; Vinagre, AM | 1 |
| Castelletti, S; Crotti, L; Dagradi, F; Gnecchi, M; Parati, G; Sala, L; Schwartz, PJ; Spazzolini, C | 1 |
| De Wachter, E; Vanderhelst, E; Verbanck, S; Vincken, S | 1 |
| De la Hoz, D; Restrepo-Gualteros, SM; Villamil Osorio, M | 1 |
| Palange, P; Righelli, D; Savi, D; Schiavetto, S; Simmonds, NJ | 1 |
| Alexiou, S; Cheng, PC; Rubenstein, RC | 1 |
| Bijvelds, MJC; Bose, SJ; Bot, AGM; Cai, Z; de Jonge, HR; Liu, J; Sheppard, DN; Wang, Y | 1 |
| Bratcher, PE; Chioccioli, M; Cicuta, P; Feriani, L; Kotar, J | 1 |
| De Biase, RV; Gnessi, L; Lenzi, A; Lubrano, C; Pascucci, C; Quattrucci, S; Savi, D | 1 |
| Fischer, AJ; Fox, C; Gates, LK; McLearn-Montz, AJ; Milavetz, F; Murry, LT; Porterfield, HS; Sabus, A; Singh, SB | 1 |
| Giembycz, MA; Hamed, O; Joshi, R; Joshi, T; Mostafa, MM; Newton, R; Yan, D | 1 |
| Balfour-Lynn, IM | 1 |
| Bolan, C; Cortese, C; Harnois, D; Mallea, J | 1 |
| Cantón, R; Garcia-Castillo, M; Gargallo-Viola, D; López, Y; Morrissey, I; Vila, J; Zsolt, I | 1 |
| Baldelli, S; Cattaneo, D; Clementi, E; Colombo, C; Cozzi, V; Faelli, NML; Fusi, M; Russo, M | 1 |
| Beekman, JM; Chen, KG; Zheng, W; Zhong, P | 1 |
| Brannan, J; Cookson, K; Dorahy, DJ; Thiruchelvam, T; Wark, PAB | 1 |
| Andriessen, A; Bhatia, N; Grada, A; Patele, D; Schachner, L | 1 |
| Burki, TK | 1 |
| Beiersdorf, N; Groten, T; Jaudszus, A; Lorenz, M; Mainz, JG; Michl, RK; Schneider, U | 1 |
| Bell, SC; Fridman, M; Kinnman, N; Macey, J; MacGregor, G; Madge, S; Mainz, JG; Narayanan, S; Suthoff, ED | 1 |
| Connett, GJ | 1 |
| Ahmadi, S; Bartlett, C; Bear, CE; Gonska, T; Ip, W; Jiang, J; Laselva, O; Lew, A; Moraes, TJ; Ouyang, H; Wellhauser, L; Wu, YS; Xia, S | 1 |
| Alper, CJ; Bacon, R; Greenwood, BC; Jeffrey, PL; Lenz, K; Stevens, K; Tesell, MA | 1 |
| Fitch, J; Hayes, D; Jaramillo, L; Kopp, BT; Mejias, A; Palacios, S; Partida-Sanchez, S; Ramilo, O; Robledo-Avila, F; Shrestha, CL; White, P; Woodley, F; Zhang, S | 1 |
| Bellaire, S; Bwirire, D; Conrath, K; Corveleyn, S; Fischer, R; Gleiber, W; Hector, A; Kempa, A; Muller, K; Pano, A; Santermans, E; Schwarz, C; Sutharsan, S; Van de Steen, O; van Koningsbruggen-Rietschel, S; Van Osselaer, N | 1 |
| Cantón, R; Gargallo-Viola, D; López, Y; Tato, M; Vila, J; Zsolt, I | 2 |
| Akshintala, VS; Cebotaru, L; Cutting, GR; Dezube, R; Faghih, M; Jennings, MT; Kamal, A; Lechtzin, N; Merlo, CA; Singh, VK; West, NE; Whitcomb, DC | 1 |
| Hollis, A | 1 |
| Cuyx, S; De Boeck, K | 1 |
| Chou, FY; Hamilton, CM; Lam, GY; Quon, BS; Sergeev, V; Wilcox, PG | 1 |
| Douros, K; Loukou, I; Moustaki, M; Plyta, M | 1 |
| Ehrhardt, A; Hong, JS; Joshi, D; Sorscher, EJ | 1 |
| Barker, D; Burr, L; Dorahy, D; France, M; Greville, H; Middleton, P; Tong, K; Visser, S; Wainwright, C; Wark, P | 1 |
| Mall, MA; Mayer-Hamblett, N; Rowe, SM | 1 |
| Durieu, I; Garcia, S; Nave, V; Olivereau, L; Perceval, M; Rabilloud, M; Reynaud, Q | 1 |
| Albareda López, N; Grimalt, R; Masramon, X; Torrelo, A; Zsolt, I | 1 |
| Fujikawa, K; Fujikawa, M; Ikeda, F; Kanayama, S; Kitano, T; Matsumoto, T; Mori, S; Nakamura, A; Okamoto, K; Tabara, K; Tamura, R; Uratsuji, H | 1 |
| Carson, S; Christianson, MS; Claudio, AT; Lechtzin, N; Montemayor, K; West, NE | 1 |
| Cryan, SA; Cutrona, MB; De Santi, C; Fernández Fernández, E; Gaul, R; Glasgow, A; Greene, CM; Harvey, BJ; Hawkins, F; Henshall, DC; Hurley, K; Linnane, B; MacLoughlin, R; McNally, P; Mitash, N; Mu, F; Oglesby, IK; Raoof, R; Simpson, JC; Swiatecka-Urban, A; Vencken, S | 1 |
| Bear, CE; Deber, CM; Laselva, O; Stone, TA | 1 |
| Clifton, I; Etherington, C; Holbrook, J; Jarosz-Griffiths, HH; Lara-Reyna, S; Martinon, F; McDermott, MF; Mehta, A; Peckham, D; Savic, S; Scambler, T; Spoletini, G; Whitaker, P; Wong, CH | 1 |
| Daniels, MLA; Ebert, CS; Farzal, Z; Kimple, AJ; Lee, SE; Senior, BA; Thorp, BD; Zanation, AM | 1 |
| Fajac, I; Girodon, E | 1 |
| Abely, M; Bounyar, L; Chatron, E; Chiron, R; Cosson, L; Dominique, S; Durieu, I; Gerardin, M; Kessler, L; Kessler, R; Mankikian, J; Melly, L; Misgault, B; Porzio, M; Reynaud, Q; Ronsin-Pradel, O; Touzet, S; Troussier, F; Weiss, L | 1 |
| Cottrill, KA; Farinha, CM; McCarty, NA | 1 |
| Aller, SG; Bacsa, J; Breton, GW; Doiron, JE; Le, CA; Martin, KL; Turlington, M | 1 |
| Kessler, L | 1 |
| Aalbers, BL; Arets, HGM; Bronsveld, I; de Kiviet, AC; de Winter-de Groot, KM; Heijerman, HGM; Hofland, RW; Kruijswijk, MA; Michel, S; Schotman, S; van der Ent, CK; van Oirschot-van de Ven, MMM | 1 |
| Al Shadfan, LM; Altıntaş, DU; Aslan, AT; Başaran, AE; Bingöl, A; Çakır, E; Çaltepe, G; Can, D; Çekiç, Ş; Çelebioğlu, E; Cinel, G; Çobanoğlu, N; Çokuğraş, H; Demir, E; Doğru, D; Emiralioğlu, N; Ercan, Ö; Gürsoy, TR; Hangül, M; Harmancı, K; Karagöz, D; Kartal Öztürk, G; Kılıç, M; Kılınç, AA; Kiper, N; Korkmaz Ekren, P; Köse, M; Özcan, G; Özçelik, U; Özdemir, A; Özdoğan, Ş; Pekcan, S; Sapan, N; Şen, HS; Şen, V; Şişmanlar Eyüboğlu, T; Süleyman, A; Tamay, Z; Topal, E; Tuğcu, G; Yalçın, E; Yazan, H; Yıldırım, GK; Yılmaz, Ö; Yüksel, H | 1 |
| Boyle, KG; Dhillon, SS; Guenette, JA; Mitchell, RA; Quon, BS; Ramsook, AH; Wilcox, PG | 1 |
| Ballmann, M; Glass, A; Holl, R; Prinz, N | 1 |
| Keeling, KM; Rowe, SM; Sharma, J | 1 |
| Clancy, JP; Donaldson, SH; Khan, U; Ratjen, F; Rowe, SM; Sagel, SD; Shaw, M | 1 |
| Mall, MA; Naisbitt, DJ; Ogese, MO; Roehmel, JF; Rohrbach, A | 1 |
| Cholon, DM; Esther, CR; Gentzsch, M; Guhr Lee, TN; Quinney, NL | 1 |
| Eudaley, S | 1 |
| Caputo, M; Carnovale, V; Castaldo, G; Cernera, G; Comegna, M; Corso, G; Gelzo, M; Iacotucci, P | 1 |
| George, A; Goetz, DM; Sawicki, GS; Smith, B | 1 |
| Brown, J; de Vries, JM; Fabbrini, AL; Green, D; Kidder, M; Kucera, JN; Wilsey, M | 1 |
| Abely, M; Biouhee, T; Bui, S; Burgel, PR; Chiron, R; Corvol, H; Dehillotte, C; Durieu, I; Hubert, D; Lemonnier, L; Macey, J; Marguet, C; Martin, C; Mely, L; Munck, A; Murris-Espin, M; Paillasseur, JL; Porzio, M; Prevotat, A; Reix, P; Sermet-Gaudelus, I; Silva, JD | 1 |
| Aureli, M; Bassi, R; Cabrini, G; Chiricozzi, E; Dechecchi, MC; Lippi, G; Loberto, N; Mancini, G; Mauri, L; Olioso, D; Pedemonte, N; Pesce, E; Schiumarini, D; Sonnino, S; Tamanini, A | 1 |
| Finnegan, R; O'Grady, E; Ryan, S; Smyth, A; Williamson, M | 1 |
| Aridgides, DS; Armstrong, DA; Ashare, A; Dessaint, JA; Hampton, TH; Hazlett, HF; Mellinger, DL; Nymon, AB | 1 |
| Afonso, S; Amaral, MD; Botelho, HM; da Paula, AC; Farinha, CM; Felício, V; Lobo, MJ; Uliyakina, I | 1 |
| Aissat, A; Bizard, L; Decrouy, X; Degrugillier, F; Fanen, P; Jiang, C; Prulière-Escabasse, V; Rotin, D; Simon, S; Simonneau, B | 1 |
| Armirotti, A; Bandiera, T; Bertozzi, SM; Braccia, C; Giraudo, A; Liessi, N; Pedemonte, N; Pesce, E | 1 |
| Finkbeiner, WE; Haggie, PM; Janahi, IA; Nielson, DW; Phuan, PW; Rivera, AA; Tan, JA; Thomas, MM; Verkman, AS | 1 |
| Arest, CF; De Jong, E; Falsafi, R; Garratt, LW; Hancock, REW; Hillas, J; Iosifidis, T; Kicic, A; Kicic-Starcevich, E; Lannigan, FJ; Lee, AHY; Ling, KM; Looi, K; Martinovich, KM; Montgomery, ST; Shaw, NC; Smith, ML; Stick, SM; Sutanto, EN; Vijayasekaran, S | 1 |
| Beekman, JM; Graeber, SY; Hirtz, S; Kruisselbrink, E; Mall, MA; van der Ent, CK; van Mourik, P; Vonk, AM | 1 |
| Amaral, MD; Botelho, HM; Centeio, R; Clarke, LA; Doušová, T; Farinha, CM; Holubová, A; Hwang, TC; Kunzelmann, K; Railean, V; Ramalho, S; Silva, IAL; Valášková, I; Yeh, JT | 1 |
| Beaufils, F; Bui, S; Burgel, PR; Delhaes, L; Enaud, R; Fayon, M; Lamireau, T; Mas, E; Maumus, P; Mittaine, M; Tétard, C | 1 |
| Bartlett, C; Bear, CE; Gonska, T; Gunawardena, TNA; Laselva, O; Moraes, TJ; Ouyang, H; Popa, A | 1 |
| Xia, X | 1 |
| Ejiofor, LCK; Jensen-Fangel, S; Mathiesen, IHM; Olesen, HV; Pedersen, CL; Philipsen, LKD; Pressler, T; Skov, M | 1 |
| Antos, N; Beisang, D; Billings, J; Frederick, C; Heltshe, SL; Mann, M; Moheet, A; Moran, A; Rowe, SM; Sagel, SD; VanDalfsen, JM; Zhang, L | 1 |
| Edelman, A; Gauthier, S; Guerrera, IC; Hinzpeter, A; Jung, V; Martignetti, L; Nguyen-Khoa, T; Pranke, I; Semeraro, M; Sermet-Gaudelus, I; Stoven, V | 1 |
| Bos, LDJ; Kemper, EM; Maitland-van der Zee, AH; Majoor, CJ; Mathôt, RAA; Neerincx, AH; van der Meer-Vos, M; Vonk, SEM | 1 |
| Choudhury, P; Colecraft, HM; Jain, A; Kanner, SA; Shuja, Z | 1 |
| Duncan, M; Ellis, M; Harris, RA; Jha, L; Keating, D; Kotsimbos, T; Tian, S; Urquhart, DS; Wilson, J; You, X | 1 |
| Lechtzin, N; Montemayor, K | 1 |
| Cagnina, RE; Sawicki, GS | 1 |
| Dave, K; Davies, JC; Dobra, R; Matthews, J; Saunders, C; Scott, S; Simmonds, NJ | 1 |
| VanDevanter, DR | 1 |
| Kuntz, KM; Pearson, SD; Rind, DM; Seidner, M; Tice, JA; Wherry, K | 1 |
| Chilvers, MA; Cornell, AG; Davies, JC; Han, Z; Milla, C; Owen, CA; Ratjen, F; Tian, S | 1 |
| Bardin, E; Berhal, F; Chevalier, B; Golec, A; Gravier-Pelletier, C; Hayes, K; Hinzpeter, A; Pastor, A; Pranke, I; Prestat, G; Semeraro, M; Sermet-Gaudelus, I | 1 |
| Andriessen, A; Benjamin, LT; Claro, C; Eichenfield, LF; Esposito, SM; Keller, L; Kircik, L; Kwong, PC; McCuaig, C; Schachner, LA | 1 |
| Clancy, JP; Konstan, MW; Mayer-Hamblett, N; Odem-Davis, K; Rowe, SM; Skalland, M; VanDevanter, DR; Zemanick, ET | 1 |
| Battezzati, A; Bisogno, A; Colombo, C; Daccò, V; Foppiani, A; Gambazza, S; Giana, A; Leone, A; Mari, A; Nazzari, E | 1 |
| Chen, J; Conrath, K; Falk Libby, E; Li, Y; Mutyam, V; Peng, N; Rowe, SM; Sharma, J; Singh, AK; Tang, LP | 1 |
| Lebecque, P; Thimmesch, M | 1 |
| Anderson, B; Azaro, A; Benhadji, KA; Cassier, PA; Italiano, A; Massard, C; Merchan, J; Oakley, G; Pant, S; Tap, WD; Yu, D; Yuen, E | 1 |
| Amato, F; Castaldo, G; Castellani, C; Ferrari, B; Galietta, LJV; Taccetti, G; Terlizzi, V | 1 |
| Course, CW; Doull, I; Edmondson, C | 1 |
| Adam, HJ; Baxter, M; Karlowsky, JA; Lagace-Wiens, PRS; Zhanel, GG | 1 |
| Bertini, M; Casiraghi, A; Cipolli, M; Fedrigo, A; Iansa, P; Kleinfelder, K; Melotti, P; Minghetti, P; Pintani, E; Sorio, C; Treggiari, D; Tridello, G | 1 |
| Andriessen, A; Hebert, AA; Hohl, D; Kircik, LH; Kwong, P; Lynde, CW; Oza, V; Schachner, LA; Torrelo, A | 1 |
| Chilvers, M; Cornell, AG; Hoppe, JE; McColley, SA; McNamara, JJ; Owen, CA; Ratjen, F; Tian, S; Zahigian, R | 1 |
| Bennett, WD; Bhambhvani, PG; Ceppe, A; Clancy, JP; Corcoran, TE; Donaldson, SH; Laube, BL; Mogayzel, P; Pilewski, JM; Ratjen, F; Rowe, SM; Sagel, SD; Wu, J | 1 |
| Bessaci-Kabouya, K; Bokov, P; Bui, S; Burgel, PR; Choukroun, ML; Da Silva, J; Gerardin, M; Ioan, I; Le Bourgeois, M; Paillasseur, JL; Reix, P; Tatopoulos, A | 1 |
| Harwood, KH; Jarnicki, A; McQuade, RM; Schneider-Futschik, EK | 1 |
| Fortina, AB; Galli, L; Novelli, A; Ruggiero, G; Stefani, S | 1 |
| Bailly-Botuha, C; Berteloot, L; Chedevergne, F; Cornet, M; Dana, J; Debray, D; Drummond, D; Girard, M; Le Bourgeois, M; Nguyen-Khoa, T; Schneider-Futschik, EK; Sermet-Gaudelus, I | 1 |
| Chróinín, MN; Croinin, K; Crowley, J; Mullane, D | 1 |
| Bálint, ER; Balla, Z; Czira, B; Fűr, G; Hegyi, P; Kiss, L; Kormányos, ES; Kovács, DP; Maléth, J; Orján, EM; Pallagi, P; Rakonczay, Z; Szűcs, A; Venglovecz, V | 1 |
| Bruegel, M; Habler, K; Kalla, AS; Nährig, S; Paal, M; Rychlik, M; Teupser, D; Vogeser, M | 1 |
| Kondapalli, VGCS; Mullangi, S; Panchakarla, RK; Ravi, PR | 1 |
| Zhang, B; Zhang, S | 1 |
| Burgel, PR; Campredon, A; Chassagnon, G; Vakalopoulou, M | 1 |
| Astori, A; Gupta, GD; Iazzi, M; Raught, B; St-Germain, J | 1 |
| Gao, J; Geng, X; Liu, L; Wang, T; Zhang, J | 1 |
| Borowitz, D; Clancy, JP; Gabel, ME; Gelfond, D; Roach, C; Rowe, SM; Sagel, SD; Wang, H | 1 |
| Jensen, JH; Leo-Hansen, C; Olesen, HV; Pedersen, CL; Philipsen, LKD; Rysgaard, UK; Sørensen, L | 1 |
| Edwards, C; Lee, T; Naisbitt, DJ; Nissenbaum, C; Ogese, MO; Pirmohamed, M; Semic-Jusufagic, A; Wilkinson, M | 1 |
| Neeland, MR; Ranganathan, S; Shanthikumar, S | 1 |
| Kanayama, S; Kurokawa, I; Yamasaki, O | 1 |
66 review(s) available for alpha-aminopyridine and carbostyril
| Article | Year |
|---|---|
Update on new pulmonary therapies.
Topics: Aminophenols; Aminopyridines; Anti-Infective Agents; Anti-Inflammatory Agents; Benzodioxoles; Biomarkers; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genetic Markers; Genetic Therapy; Humans; Mutation; Oxadiazoles; Quinolones; Respiratory System Agents; Saline Solution, Hypertonic | 2009 |
[Diseases of the lung and air passages 2010].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aminopyridines; Asthma; Benzamides; Cyclopropanes; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Indans; Lung Diseases; Lung Neoplasms; Neoplasm Staging; Phosphodiesterase 4 Inhibitors; Pneumonia, Bacterial; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones | 2010 |
A review of the advances in chronic obstructive pulmonary disease treatment.
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Indans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Randomized Controlled Trials as Topic; Scopolamine Derivatives; Tiotropium Bromide | 2012 |
Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Clinical Trials as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Therapy, Combination; Humans; Molecular Targeted Therapy; Mutation; Quinolones | 2013 |
Cystic fibrosis transmembrane regulator correctors and potentiators.
Topics: Aminophenols; Aminopyridines; Bayes Theorem; Benzodioxoles; Chloride Channels; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Discovery; Humans; Mutation; Quinolones; Randomized Controlled Trials as Topic; Technology, Pharmaceutical | 2013 |
[Therapeutic update in cystic fibrosis].
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Mutation; Oxadiazoles; Quinolones | 2014 |
Cystic fibrosis--what are the prospects for a cure?
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genetic Therapy; Humans; Quinolones | 2014 |
F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Design; Humans; Mutation; Patents as Topic; Quinolones | 2015 |
Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
Topics: Aminophenols; Aminopyridines; Animals; Benzodioxoles; Clinical Trials as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Design; Homozygote; Humans; Mice; Molecular Targeted Therapy; Mutation; Protein Folding; Quinolones | 2015 |
Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA; DNA Mutational Analysis; Humans; Mutation; Oxadiazoles; Quinolones | 2015 |
Update in Cystic Fibrosis 2014.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genetic Markers; Humans; Mucociliary Clearance; Quinolones; Treatment Outcome | 2015 |
Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA Mutational Analysis; Drug Combinations; Genetic Predisposition to Disease; Humans; Lung; Mutation; Patient Selection; Phenotype; Precision Medicine; Quinolones; Respiratory System Agents; Treatment Outcome | 2015 |
Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.
Topics: Albuterol; Aminopyridines; Beclomethasone; Benzamides; Benzyl Alcohols; Bronchodilator Agents; Budesonide; Chlorobenzenes; Cyclopropanes; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Glucocorticoids; Humans; Indans; Ipratropium; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Quinolones; Survival Rate; Theophylline; Tiotropium Bromide; Triamcinolone | 2015 |
[New therapies for cystic fibrosis targeting the CFTR gene or the CFTR protein].
Topics: Age Factors; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Genetic Therapy; Humans; Molecular Targeted Therapy; Quinolones | 2016 |
[Treatment of Cystic Fibrosis with CFTR Modulators].
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Biomarkers, Tumor; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dose-Response Relationship, Drug; Drug Combinations; Evidence-Based Medicine; Genetic Markers; Genetic Predisposition to Disease; Humans; Precision Medicine; Quinolones; Treatment Outcome | 2016 |
Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Biomarkers; Clinical Trials as Topic; Critical Pathways; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Genetic Therapy; Genotype; Humans; Molecular Targeted Therapy; Mutation; Quality of Life; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
New and emerging targeted therapies for cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Clinical Trials as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Discovery; Drug Therapy, Combination; Forced Expiratory Volume; Forecasting; Genetic Therapy; Homozygote; Humans; Molecular Targeted Therapy; Mutation; Oxadiazoles; Phosphodiesterase 5 Inhibitors; Practice Guidelines as Topic; Precision Medicine; Quinolones | 2016 |
Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Clinical Trials as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Therapy, Combination; Humans; Mutation; Precision Medicine; Quinolones | 2016 |
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chloride Channel Agonists; Clinical Trials, Phase III as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Homozygote; Humans; Lung; Male; Middle Aged; Quinolones; Randomized Controlled Trials as Topic; Respiratory Function Tests; Treatment Outcome; Young Adult | 2016 |
Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Lung; Mutation; Quinolones | 2016 |
Pharmacological profiles and clinical effects of ozenoxacin lotion for the treatments of acne vulgaris and superficial infection of the skin.
Topics: Acne Vulgaris; Aminopyridines; Anti-Bacterial Agents; Clinical Trials as Topic; Humans; Microbial Viability; Multicenter Studies as Topic; Quinolones; Skin Cream | 2016 |
New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Molecular Targeted Therapy; Mutation; Quinolones | 2016 |
Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Approval; Drug Combinations; Humans; Quinolones; United States; United States Food and Drug Administration | 2017 |
Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies.
Topics: Aminophenols; Aminopyridines; Anti-Bacterial Agents; Benzodioxoles; Chloride Channel Agonists; Clinical Trials as Topic; Comparative Effectiveness Research; Cystic Fibrosis; Disease Progression; Drug Combinations; Humans; Pseudomonas Infections; Quinolones; Standard of Care; Treatment Outcome | 2017 |
Effects of new and emerging therapies on gastrointestinal outcomes in cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Body Mass Index; Chloride Channel Agonists; Cystic Fibrosis; Digestive System; Drug Combinations; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Intestinal Diseases; Liver Diseases; Probiotics; Quinolones; Treatment Outcome; Weight Gain | 2017 |
Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease.
Topics: Aftercare; Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cholagogues and Choleretics; Cystic Fibrosis; Drug Combinations; Elasticity Imaging Techniques; Humans; Liver Diseases; Liver Transplantation; Quinolones; Ursodeoxycholic Acid | 2017 |
The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Animals; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Cytochrome P-450 CYP3A; Drug Combinations; Drug Interactions; Humans; Mutation; Quinolones | 2017 |
Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
Topics: Aminophenols; Aminopyridines; Animals; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Forced Expiratory Volume; Humans; Molecular Targeted Therapy; Mutation; Quinolones | 2017 |
Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Biomarkers; Clinical Trials, Phase II as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Therapy, Combination; Humans; Indoles; Precision Medicine; Quinolones; Respiratory System Agents | 2018 |
Cystic fibrosis papers of the year 2017.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Management; Drug Combinations; Humans; Lung; Membrane Transport Modulators; Mutation; Quinolones; Respiratory Function Tests; Time | 2018 |
The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Canada; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Genetic Therapy; Humans; Incidence; Mutation, Missense; Precision Medicine; Program Development; Quinolones; RNA | 2019 |
Mini Review: Chronic obstructive pulmonary disease, its new drug treatments and strategies: A review.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Indans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2018 |
Ozenoxacin: A Novel Drug Discovery for the Treatment of Impetigo.
Topics: Aminopyridines; Animals; Anti-Bacterial Agents; Drug Discovery; Drug Interactions; Humans; Impetigo; Quinolones | 2019 |
Ion Channel Modulators in Cystic Fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Genotype; Humans; Indoles; Ion Channels; Precision Medicine; Quinolones | 2018 |
Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug Development; Humans; Indoles; Molecular Targeted Therapy; Mutation; Quinolones | 2018 |
Ozenoxacin: A Novel Topical Quinolone for Impetigo.
Topics: Administration, Topical; Aminopyridines; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Female; Humans; Impetigo; Male; Methicillin-Resistant Staphylococcus aureus; Quinolones; Staphylococcus aureus; Treatment Outcome | 2018 |
Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Genetic Therapy; Humans; Indoles; Mutation; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic | 2018 |
Tezacaftor for the treatment of cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Genotype; Humans; Indoles; Mutation; Quinolones | 2018 |
Theratyping in cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Gene Editing; Genetic Therapy; Genotype; Humans; Indoles; Mutation; Organoids; Oxadiazoles; Precision Medicine; Quinolones | 2018 |
CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Male; Molecular Targeted Therapy; Organ Transplantation; Quinolones; Young Adult | 2018 |
Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Combined Modality Therapy; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dose-Response Relationship, Drug; Homozygote; Humans; Mutation; Quinolones | 2019 |
Ozenoxacin: a review of preclinical and clinical efficacy.
Topics: Aminopyridines; Animals; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial; Humans; Impetigo; Quinolones; Staphylococcus aureus; Treatment Outcome | 2019 |
Cystic fibrosis transmembrane conductance regulator modulators: Present and future in cystic fibrosis treatment. A review.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Indoles; Precision Medicine; Quality of Life; Quinolones | 2019 |
Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Child; Child, Preschool; Clinical Trials as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Mutation; Quinolones; Treatment Outcome | 2019 |
Clinical papers of the year 2018 - Cystic fibrosis.
Topics: Administration, Inhalation; Aminophenols; Aminopyridines; Anti-Bacterial Agents; Azithromycin; Benzodioxoles; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Chloride Channel Agonists; Cough; Cross Infection; Cystic Fibrosis; Disease Progression; Drug Combinations; Drug Therapy, Combination; Humans; Indoles; Lung Transplantation; Microbiological Techniques; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Nebulizers and Vaporizers; Proton Pump Inhibitors; Pseudomonas aeruginosa; Pseudomonas Infections; Pyrazoles; Pyridines; Pyrrolidines; Quinolones; Randomized Controlled Trials as Topic; Saline Solution, Hypertonic; Specimen Handling; Sputum; Treatment Outcome; Tuberculosis, Pulmonary | 2020 |
Cystic Fibrosis-Associated Liver Disease in Lung Transplant Recipients.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Incidence; Liver Cirrhosis; Liver Transplantation; Lung Transplantation; Mutation; Postoperative Care; Quinolones; Survival Rate; Transplant Recipients; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
A systematic Cochrane Review of correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Therapy, Combination; Humans; Indoles; Quinolones; Treatment Outcome | 2019 |
Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Biological Assay; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genotype; Humans; Molecular Targeted Therapy; Mutation; Organoids; Pharmacogenomic Variants; Quinolones; Stem Cells | 2019 |
Topical Ozenoxacin Cream 1% for Impetigo: A Review
Topics: Aminopyridines; Anti-Bacterial Agents; Antimicrobial Stewardship; Clinical Decision-Making; Drug Resistance, Bacterial; Humans; Impetigo; Mutation; Patient Selection; Practice Guidelines as Topic; Quinolones; Skin Cream; Staphylococcus aureus; Treatment Outcome | 2019 |
Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug Design; Drug Therapy, Combination; Humans; Quinolones | 2019 |
Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genetic Therapy; Humans; Indoles; Mutation; Quinolones; Randomized Controlled Trials as Topic | 2019 |
The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Mutation; Quinolones; Signal Transduction | 2020 |
Cystic fibrosis precision therapeutics: Emerging considerations.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Indoles; Precision Medicine; Quinolones | 2019 |
Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelial Sodium Channel Blockers; Humans; Indoles; Molecular Targeted Therapy; Mucociliary Clearance; Mutation; Precision Medicine; Pyrazoles; Pyridines; Pyrrolidines; Quinolones | 2020 |
Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chronic Disease; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Approval; Humans; Indoles; Mutation; Nasal Mucosa; Otolaryngologists; Pyrazoles; Pyridines; Pyrrolidines; Quinolones | 2020 |
The bidirectional relationship between CFTR and lipids.
Topics: Aminophenols; Aminopyridines; Animals; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Epithelial Cells; Humans; Lung; Membrane Lipids; Membrane Microdomains; Mutation; Protein Conformation; Protein Stability; Protein Transport; Quinolones; Structure-Activity Relationship | 2020 |
Cystic fibrosis 2019: Year in review.
Topics: Administration, Inhalation; Aminophenols; Aminopyridines; Anti-Bacterial Agents; Azithromycin; Benzodioxoles; Carrier State; Chloride Channel Agonists; Cystic Fibrosis; Drug Combinations; Exercise; Health Services Accessibility; Healthcare Disparities; Humans; Indoles; Inflammation; Physical Therapy Modalities; Pseudomonas Infections; Pyrazoles; Pyridines; Quinolines; Quinolones; Saline Solution, Hypertonic | 2020 |
Pharmacological approaches for targeting cystic fibrosis nonsense mutations.
Topics: Aminophenols; Aminopyridines; Animals; Benzodioxoles; Codon, Nonsense; Cystic Fibrosis; Dose-Response Relationship, Drug; Humans; Indoles; Molecular Structure; Mutation; Pyrazoles; Pyridines; Pyrrolidines; Quinolones; Structure-Activity Relationship | 2020 |
Ozenoxacin (Xepi) for the Treatment of Impetigo.
Topics: Administration, Topical; Aminopyridines; Anti-Bacterial Agents; Child; Child, Preschool; Humans; Impetigo; Infant; Quinolones | 2020 |
Entering the era of highly effective modulator therapies.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Child; Chloride Channel Agonists; Clinical Trials as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Therapy, Combination; Humans; Indoles; Mutation; Pyrazoles; Pyridines; Pyrrolidines; Quinolones | 2021 |
Modulators of CFTR. Updates on clinical development and future directions.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Clinical Trials as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Development; Humans; Indoles; Quinolones | 2021 |
Do Antimicrobial Resistance Patterns Matter? An Algorithm for the Treatment of Patients With Impetigo.
Topics: Aminopyridines; Anti-Bacterial Agents; Antimicrobial Stewardship; Bridged Bicyclo Compounds, Heterocyclic; Critical Pathways; Delphi Technique; Diterpenes; Drug Resistance, Bacterial; Evidence-Based Medicine; Fusidic Acid; Humans; Impetigo; Microbial Sensitivity Tests; Mupirocin; Practice Guidelines as Topic; Quinolones; Skin Cream; Staphylococcus aureus; Streptococcus pyogenes; Systematic Reviews as Topic | 2021 |
Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Genetic Variation; Humans; Indoles; Outcome Assessment, Health Care; Pyrazoles; Pyridines; Pyrrolidines; Quinolones | 2021 |
Treatment of Impetigo and Antimicrobial Resistance.
Topics: Administration, Cutaneous; Aminopyridines; Anti-Bacterial Agents; Antimicrobial Stewardship; Drug Prescriptions; Drug Resistance, Bacterial; Humans; Impetigo; Microbial Sensitivity Tests; Practice Guidelines as Topic; Quinolones; Staphylococcus aureus; Treatment Outcome | 2021 |
Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis.
Topics: Aminophenols; Aminopyridines; Anti-Inflammatory Agents; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Indoles; Inflammation; Ion Transport; Lung; Macrophages; Pneumonia; Quinolones; Signal Transduction | 2021 |
Pediatric impetigo: an expert panel opinion about its main controversies.
Topics: Aminopyridines; Anti-Bacterial Agents; Cellulitis; Child; Humans; Impetigo; Quinolones | 2022 |
21 trial(s) available for alpha-aminopyridine and carbostyril
| Article | Year |
|---|---|
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Base Sequence; Benzodioxoles; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Heterozygote; Homozygote; Humans; Male; Quinolones; Sequence Deletion; Sweat; Young Adult | 2014 |
Systemic bioavailability, safety and tolerability of topical ozenoxacin in healthy adult volunteers.
Topics: Administration, Topical; Adolescent; Adult; Aminopyridines; Anti-Bacterial Agents; Biological Availability; Drug Tolerance; Humans; Male; Middle Aged; Quinolones; Skin; Volunteers; Young Adult | 2014 |
Skin tissue exposure of once- versus twice-daily topical ozenoxacin 2% cream: a Phase I study in healthy volunteers.
Topics: Administration, Topical; Adolescent; Adult; Aminopyridines; Anti-Bacterial Agents; Drug Administration Schedule; Female; Healthy Volunteers; Humans; Male; Middle Aged; Quinolones; Skin; Young Adult | 2014 |
Cumulative irritation, sensitizing potential, phototoxicity and photoallergy of ozenoxacin in healthy adult volunteers.
Topics: Adolescent; Adult; Aged; Aminopyridines; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Stability; Female; Humans; Male; Middle Aged; Quinolones; Skin; Volunteers; Young Adult | 2014 |
Systemic bioavailability and safety of twice-daily topical ozenoxacin 1% cream in adults and children with impetigo.
Topics: Administration, Topical; Adolescent; Adult; Aminopyridines; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Female; Humans; Impetigo; Male; Middle Aged; Pruritus; Quinolones; Young Adult | 2014 |
Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial.
Topics: Adolescent; Aminopyridines; Anti-Bacterial Agents; Bridged Bicyclo Compounds, Heterocyclic; Child; Child, Preschool; Diterpenes; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Impetigo; Male; Ointments; Quinolones | 2014 |
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Homozygote; Hospitalization; Humans; Male; Middle Aged; Mutation; Quinolones; Young Adult | 2015 |
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cough; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Forced Expiratory Volume; Homozygote; Humans; Lung; Male; Mutation; Quinolones; Time; Treatment Outcome; Young Adult | 2017 |
Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.
Topics: Adult; Aldehyde Oxidoreductases; Aminophenols; Aminopyridines; Benzodioxoles; Biological Availability; Biphenyl Compounds; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Cytochrome P-450 CYP3A Inducers; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Monitoring; Female; Humans; Male; Membrane Transport Modulators; Mutation; Pharmacogenetics; Quinolones; Rifampin; Treatment Outcome | 2017 |
Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aminopyridines; Anti-Bacterial Agents; Child; Child, Preschool; Double-Blind Method; Drug Resistance, Bacterial; Female; Humans; Impetigo; Infant; Male; Quinolones; Skin Cream; Staphylococcal Infections; Streptococcal Infections; Streptococcus pyogenes; Young Adult | 2018 |
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV
Topics: Adolescent; Adult; Aged; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Disease Progression; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Quinolones; Respiratory Function Tests; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients With Impetigo: Pooled Analysis of Phase 3 Clinical Trials.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aminopyridines; Anti-Bacterial Agents; Child; Child, Preschool; Double-Blind Method; Drug Administration Schedule; Europe; Female; Humans; Impetigo; Infant; Male; Middle Aged; Quinolones; Randomized Controlled Trials as Topic; Russia; Severity of Illness Index; South Africa; Treatment Outcome; United States; Young Adult | 2018 |
Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Disease Progression; Drug Combinations; Female; Humans; Male; Quality of Life; Quinolones; Recovery of Function; Time Factors; Treatment Outcome | 2019 |
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
Topics: Age Factors; Aminophenols; Aminopyridines; Benzodioxoles; Child, Preschool; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Therapy, Combination; Female; Homozygote; Humans; Male; Quinolones | 2019 |
GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN).
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Homozygote; Humans; Male; Mutation; Quinolones; Respiratory Function Tests; Sweat; Treatment Outcome | 2020 |
Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents.
Topics: Administration, Topical; Adolescent; Aminopyridines; Anti-Bacterial Agents; Child; Humans; Impetigo; Quinolones; Skin Cream; Treatment Outcome | 2020 |
Short-term effects of Lumacaftor/Ivacaftor (Orkambi™) on exertional symptoms, exercise performance, and ventilatory responses in adults with cystic fibrosis.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Drug Combinations; Exercise Test; Female; Forced Expiratory Volume; Humans; Male; Physical Exertion; Pulmonary Ventilation; Quinolones; Treatment Outcome; Young Adult | 2020 |
Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Quality of Life; Quinolones; Young Adult | 2020 |
VO
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Humans; Male; Oxygen Consumption; Quinolones | 2021 |
Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
Topics: Aminophenols; Aminopyridines; Australia; Benzodioxoles; Canada; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Europe; Female; Humans; Male; Mutation; Quinolones; Time; Treatment Outcome; United States | 2021 |
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Benzimidazoles; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalazines; Pyridines; Quinolones | 2021 |
206 other study(ies) available for alpha-aminopyridine and carbostyril
| Article | Year |
|---|---|
Identification and specificity studies of small-molecule ligands for SH3 protein domains.
Topics: Amino Acid Sequence; Aminoquinolines; Animals; Binding Sites; Binding, Competitive; Fluorescence Polarization; Ligands; Magnetic Resonance Spectroscopy; Mice; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Proline; Protein-Tyrosine Kinases; Quinazolines; Sequence Alignment; src Homology Domains; Structure-Activity Relationship | 2004 |
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
Topics: Azoles; Drug Discovery; Humans; Indoles; Isoindoles; Molecular Structure; NADPH Oxidase 2; NADPH Oxidases; Organoselenium Compounds; Protein Binding; Structure-Activity Relationship | 2020 |
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Topics: 4-Quinolones; Aminopyridines; Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Rifamycins | 2000 |
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
Topics: Aminopyridines; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Agonists; Haloperidol; Kainic Acid; Male; Mice; Mice, Inbred C57BL; Piperazines; Piperidines; Pyridines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thiazoles | 2005 |
A late cutaneous response in actively sensitized rats: a new method for evaluating the efficacy of antiallergic drugs.
Topics: Aminopyridines; Animals; Anti-Allergic Agents; Antigens; Cromolyn Sodium; Cyclosporine; Dinitrobenzenes; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Edema; Haptens; Hindlimb; Hypersensitivity, Delayed; Male; ortho-Aminobenzoates; Ovalbumin; Passive Cutaneous Anaphylaxis; Promethazine; Pyridines; Pyrimidinones; Quinolones; Rats; Rats, Wistar | 2006 |
Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
Topics: Aminopyridines; Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation; Quinolones; Streptococcus pneumoniae; Topoisomerase II Inhibitors | 2008 |
Chondrotoxicity and toxicokinetics of novel quinolone antibacterial agents DC-159a and DX-619 in juvenile rats.
Topics: Administration, Oral; Aminopyridines; Animals; Anti-Bacterial Agents; Area Under Curve; Cartilage, Articular; Dose-Response Relationship, Drug; Fluoroquinolones; Gene Expression Regulation; Male; Ofloxacin; Pyrrolidines; Quinolones; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Tissue Distribution | 2010 |
[Pulmonary medicine. Two new drugs for the treatment of COPD].
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2011 |
[New drugs in chronic obstructive pulmonary disease].
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2011 |
Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
Topics: Actins; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Cells, Cultured; Chemokine CCL5; Chemokine CXCL10; Connective Tissue Growth Factor; Cyclopropanes; Endothelin-1; Fibroblasts; Fibronectins; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indans; Inflammation; Lung; Phosphodiesterase 4 Inhibitors; Pulmonary Fibrosis; Quinolones; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2012 |
Pulmonology: CFTR modulators for cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Lung; Mutation; Oxadiazoles; Quinolones | 2013 |
FDA moves on breakthrough therapies.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Drug Approval; Neoplasms; Quinolones; Terminal Care; United States | 2013 |
In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria.
Topics: Aminopyridines; Anti-Bacterial Agents; Fluoroquinolones; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones | 2013 |
Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.
Topics: Aminophenols; Aminopyridines; Animals; Benzamides; Bronchi; Bronchitis, Chronic; Cells, Cultured; Cyclic AMP; Cyclopropanes; Cystic Fibrosis Transmembrane Conductance Regulator; Diarrhea; Dose-Response Relationship, Drug; Epithelial Cells; Humans; Intestinal Secretions; Intestine, Small; Membrane Potentials; Mice; Mucociliary Clearance; Phosphodiesterase 4 Inhibitors; Quinolones; Smoke; Smoking; Time Factors | 2014 |
Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values.
Topics: Aminopyridines; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Hydrogen-Ion Concentration; Levofloxacin; Microbial Sensitivity Tests; Quinolones | 2014 |
A new era in the treatment of cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genetic Therapy; Humans; Molecular Targeted Therapy; Mutation; Oxadiazoles; Quinolones | 2014 |
Direct interaction of a CFTR potentiator and a CFTR corrector with phospholipid bilayers.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis Transmembrane Conductance Regulator; Lipid Bilayers; Phospholipids; Protein Binding; Quinolones; Temperature; Unilamellar Liposomes | 2014 |
Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels.
Topics: Adenosine Triphosphate; Aminophenols; Aminopyridines; Benzodioxoles; Carrier Proteins; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Patch-Clamp Techniques; Peptide Fragments; Quinolones | 2014 |
The stony road to phe508del CFTR pharmacotherapy: smoothing the first rock.
Topics: Aminophenols; Aminopyridines; Base Sequence; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Male; Quinolones; Sequence Deletion | 2014 |
A cocktail drug therapy for patients with cystic fibrosis?
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Quinolones | 2014 |
Ozenoxacin: a review of absorption, dermal exposure and toxicity, tolerability and safety studies.
Topics: Aminopyridines; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Evaluation; Drug Tolerance; Humans; Quinolones; Skin | 2014 |
In vitro percutaneous absorption and metabolism of ozenoxacin in excised human skin.
Topics: Aminopyridines; Anti-Bacterial Agents; Drug Evaluation; Humans; In Vitro Techniques; Quinolones; Skin; Skin Absorption | 2014 |
In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci.
Topics: Aminopyridines; Anti-Bacterial Agents; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Polymerase Chain Reaction; Quinolones; Selection, Genetic; Sequence Analysis, DNA | 2015 |
Remarkable progress toward new treatments for cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Animals; Benzodioxoles; Clinical Trials, Phase III as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Animal; Forced Expiratory Volume; Humans; Mutation; Quinolones | 2014 |
Another Beginning for Cystic Fibrosis Therapy.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Male; Quinolones | 2015 |
Drug combination that corrects deficient protein in cystic fibrosis improves lung function.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Therapy, Combination; Humans; Peptide Fragments; Quinolones; Randomized Controlled Trials as Topic; Respiratory Function Tests | 2015 |
2015 American Thoracic Society International Conference.
Topics: Aminophenols; Aminopyridines; Antibodies, Monoclonal; Benzodioxoles; Congresses as Topic; Drug Therapy, Combination; Epidemiologic Methods; Gene Expression; Humans; Oxygen; Quinolones; Receptors, Interleukin-1 Type I; Respiratory System Agents; Respiratory Tract Diseases; Societies, Medical; Thoracic Surgery; United States | 2015 |
Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Gene Deletion; Homozygote; Humans; Molecular Targeted Therapy; Quinolones | 2015 |
Radical new treatments for cystic fibrosis.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Therapy, Combination; Humans; Quinolones; Randomized Controlled Trials as Topic | 2015 |
A new chapter in therapy for cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Male; Quinolones | 2015 |
[Cystic Fibrosis: toward a genetic treatment; Clostridium difficile versus Clostridium difficile].
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Biomarkers; Clostridioides difficile; Clostridium Infections; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Therapy, Combination; Humans; Mutation; Quinolones; Spores, Bacterial; Treatment Outcome | 2015 |
Precision Medicine: At What Price?
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cost-Benefit Analysis; Cystic Fibrosis; Drug Combinations; Humans; Precision Medicine; Quinolones; Respiratory System Agents; United States | 2015 |
Orkambi's Slick Unveiling Puts Insurers in a Bind.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Drug Combinations; Drug Costs; Drug Industry; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Quinolones; United States | 2015 |
A combination therapy for cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Gene Deletion; History, 20th Century; History, 21st Century; Humans; Quinolones | 2015 |
Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Bronchi; Cell Line; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Interactions; Epithelial Cells; Humans; Mutation; Quinolones | 2016 |
Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Gene Deletion; Humans; Quinolones | 2016 |
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Male; Quinolones | 2015 |
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Male; Quinolones | 2015 |
Breathing easier with combinations.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Biomedical Research; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Industry; Drug Therapy, Combination; Humans; Mutation; Quinolones | 2015 |
Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Quinolones; Randomized Controlled Trials as Topic | 2016 |
Game Changers.
Topics: Acute Disease; Aminophenols; Aminopyridines; Benzodioxoles; Brain Ischemia; Cystic Fibrosis; Drug Combinations; Endovascular Procedures; Humans; Quinolones; Rectal Neoplasms; Stroke; Transanal Endoscopic Microsurgery | 2015 |
Respiratory medications.
Topics: Administration, Inhalation; Aminopyridines; Androstadienes; Asthma; Beclomethasone; Benzamides; Cyclopropanes; Humans; Indans; Maleates; Nasal Sprays; Powders; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Tract Diseases; Rhinitis, Allergic | 2016 |
Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Body Mass Index; Cystic Fibrosis; Data Interpretation, Statistical; Disease Progression; Drug Approval; Drug Combinations; Drug Costs; Evidence-Based Medicine; Humans; Lung; Quinolones; Surveys and Questionnaires; Treatment Outcome; United States; United States Food and Drug Administration | 2016 |
[A milestone in cystic fibrosis therapy].
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Male; Quinolones | 2015 |
[Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Drug Combinations; Humans; Quinolones; Randomized Controlled Trials as Topic | 2016 |
Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
Topics: Administration, Oral; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug Costs; Drug Interactions; Humans; Membrane Transport Modulators; Mutation; Quinolones; Risk Factors; Treatment Outcome | 2016 |
In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
Topics: Administration, Cutaneous; Adolescent; Adult; Aminopyridines; Anti-Bacterial Agents; Child; Female; Fluoroquinolones; Humans; Japan; Levofloxacin; Male; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Quinolizines; Quinolones; Skin Cream; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Streptococcus pyogenes | 2016 |
Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis.
Topics: Aminophenols; Aminopyridines; Benzamides; Benzodioxoles; Cell Line; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Gene Expression Regulation; Half-Life; HEK293 Cells; Humans; Mutation; Quinolones; Thiazoles | 2016 |
Antimicrobial activities of ozenoxacin against isolates of propionibacteria and staphylococci from Japanese patients with acne vulgaris.
Topics: Acne Vulgaris; Aminopyridines; Anti-Infective Agents; Asian People; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Propionibacterium; Quinolizines; Quinolones; Staphylococcus | 2016 |
[Causal therapy is available].
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA Mutational Analysis; Drug Combinations; Humans; Quinolones | 2016 |
Cystic fibrosis drug is not cost effective, says NICE.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cost-Benefit Analysis; Cystic Fibrosis; Humans; Quinolones; Respiratory System Agents | 2016 |
Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Biological Assay; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genotype; Humans; In Vitro Techniques; Mutation; Organoids; Quinolones | 2016 |
Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cell Line; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Evaluation, Preclinical; Humans; Mutation, Missense; Protein Folding; Quinolones; Sequence Deletion | 2016 |
An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.
Topics: Aminophenols; Aminopyridines; Anti-Bacterial Agents; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Synergism; Drug Therapy, Combination; Humans; Polymyxin B; Pseudomonas aeruginosa; Quinolones | 2016 |
Cystic Fibrosis: The Dawn of a New Therapeutic Era.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Early Diagnosis; Genetic Therapy; Humans; Quinolones; Survival Rate | 2017 |
Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chromatography, High Pressure Liquid; Cystic Fibrosis; Humans; Limit of Detection; Quinolones; Sputum; Tandem Mass Spectrometry | 2016 |
Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Benzylamines; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Resistance, Neoplasm; Focal Adhesion Kinase 1; Gene Expression Profiling; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Neoplasm Invasiveness; Quinolones; Real-Time Polymerase Chain Reaction; Receptors, CXCR4; Sulfones; Transcriptome | 2017 |
Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
Topics: Aminophenols; Aminopyridines; Animals; Benzodioxoles; Cell Line; Cell Membrane; Cell-Free System; Chromatography; Cricetinae; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Hot Temperature; Humans; Mutation; Patch-Clamp Techniques; Protein Denaturation; Quinolones | 2017 |
Pregnancy among cystic fibrosis women in the era of CFTR modulators.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pregnancy Rate; Pregnancy, High-Risk; Quinolones; Risk Adjustment; United States | 2017 |
Effects of Lumacaftor/Ivacaftor in a Pediatric Cohort Homozygous for F508del-CFTR.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Quinolones | 2017 |
Bactericidal activity and post-antibiotic effect of ozenoxacin against Propionibacterium acnes.
Topics: Aminopyridines; Anti-Bacterial Agents; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Propionibacterium acnes; Quinolones | 2017 |
An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Dyspnea; Female; Forced Expiratory Volume; Humans; Logistic Models; Lung; Male; Middle Aged; Mutation; Quinolones; Retrospective Studies; Young Adult | 2017 |
Orkambi in patients with severe disease - Bumps in the road to CFTR modulation.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Quinolones | 2017 |
AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.
Topics: Aminophenols; Aminopyridines; Anniversaries and Special Events; Anti-Bacterial Agents; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Enzyme Replacement Therapy; History, 20th Century; History, 21st Century; Mutation; Periodicals as Topic; Pulmonary Medicine; Quinolones | 2017 |
Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis.
Topics: Adolescent; Aminophenols; Aminopyridines; Antidepressive Agents; Anxiety; Benzodioxoles; Child; Cognitive Behavioral Therapy; Cystic Fibrosis; Depression; Drug Combinations; Female; Humans; Membrane Transport Modulators; Quinolones; Suicidal Ideation; Suicide, Attempted; Withholding Treatment | 2017 |
Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Drug Combinations; Drug Therapy, Combination; Forced Expiratory Volume; Homozygote; Humans; Italy; Mutation; Quinolones; Surveys and Questionnaires; Treatment Outcome | 2018 |
Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy.
Topics: Aminophenols; Aminopyridines; Animals; Benzodioxoles; Biliary Tract; Cell Culture Techniques; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Cytokines; Cytoskeleton; Epithelial Cells; Fluorescent Antibody Technique; Humans; Induced Pluripotent Stem Cells; Inflammation; Mice; Microscopy, Confocal; Pyrimidines; Quinolones; Signal Transduction; src-Family Kinases | 2018 |
Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.
Topics: Aminophenols; Aminopyridines; Anti-Bacterial Agents; Benzodioxoles; Chloride Channel Agonists; Clinical Trials as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Expectorants; Genetic Therapy; Humans; Indoles; Mutation; Patient Selection; Quality of Life; Quinolones | 2017 |
Vertex CF data wow Wall Street.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Drug Combinations; Humans; Quinolones | 2017 |
Cigarette smoke activates CFTR through ROS-stimulated cAMP signaling in human bronchial epithelial cells.
Topics: Aminophenols; Aminopyridines; Autocrine Communication; Benzodioxoles; Bronchi; Calcium Signaling; Cell Line; Cyclic AMP; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelial Cells; Humans; Mutation; Oxidative Stress; Quinolones; Reactive Oxygen Species; Receptors, Prostaglandin E, EP4 Subtype; Second Messenger Systems; Secretory Pathway; Tobacco Smoke Pollution | 2018 |
Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Forced Expiratory Volume; Humans; Macrophages; Mutation; Phagocytosis; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones | 2018 |
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Case-Control Studies; Chromatography, Liquid; Cystic Fibrosis; High-Throughput Screening Assays; Humans; Quinolones; Tandem Mass Spectrometry | 2017 |
Nasospheroids permit measurements of CFTR-dependent fluid transport.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Biological Transport; Colforsin; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Mutation; Nasal Mucosa; Particle Size; Precision Medicine; Quinolones; Spheroids, Cellular | 2017 |
Treating Specific Variants Causing Cystic Fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Genetic Variation; Humans; Quinolones | 2017 |
The expression of Mirc1/Mir17-92 cluster in sputum samples correlates with pulmonary exacerbations in cystic fibrosis patients.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Biomarkers; Chloride Channel Agonists; Correlation of Data; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Drug Combinations; Drug Monitoring; Female; Gene Expression Profiling; Humans; Male; MicroRNAs; Nerve Tissue Proteins; Quinolones; Respiratory Function Tests; Respiratory System; RNA, Long Noncoding; Sputum | 2018 |
Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Forced Expiratory Volume; Homozygote; Humans; Markov Chains; Mutation; Quality-Adjusted Life Years; Quinolones; Severity of Illness Index; Treatment Outcome; United States | 2017 |
Cystic Fibrosis Transmembrane Conductance Regulator Attaches Tumor Suppressor PTEN to the Membrane and Promotes Anti Pseudomonas aeruginosa Immunity.
Topics: Aminophenols; Aminopyridines; Animals; Benzodioxoles; Cell Membrane; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Gene Expression Regulation; Humans; Mice; Mice, Inbred C57BL; Mice, Knockout; Models, Molecular; Monocytes; Phosphatidylinositol 3-Kinases; Protein Binding; Protein Conformation; Protein Transport; Proto-Oncogene Proteins c-akt; Pseudomonas aeruginosa; Pseudomonas Infections; PTEN Phosphohydrolase; Quinolones; Signal Transduction | 2017 |
Effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Blood Glucose; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Glucose Tolerance Test; Homozygote; Humans; Insulin Secretion; Male; Quinolones; Young Adult | 2018 |
Cis variants identified in F508del complex alleles modulate CFTR channel rescue by small molecules.
Topics: Alleles; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Mutation; Phenylalanine; Quinolones | 2018 |
Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Biomarkers; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Germany; Homozygote; Humans; Male; Prospective Studies; Quinolones; Young Adult | 2018 |
Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Bronchi; Cells, Cultured; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelial Cells; Humans; Interleukin-8; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones | 2018 |
Biomarkers: Their Role in CFTR Modulator Therapies from Early Development to the Clinic.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Biomarkers; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Quinolones | 2018 |
First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Genotype; Homozygote; Humans; Lung Transplantation; Male; Mutation; Prospective Studies; Quinolones; Severity of Illness Index; Switzerland | 2018 |
Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Biomarkers; Chromatography, Liquid; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Humans; Male; Metabolomics; Middle Aged; Quinolones; Treatment Outcome; Young Adult | 2018 |
Chronic β2AR stimulation limits CFTR activation in human airway epithelia.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Aminophenols; Aminopyridines; Benzodioxoles; Cell Line; Cilia; Cyclic AMP; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Interactions; Epithelial Cells; Humans; Mutation; Quinolones; Respiratory Mucosa; Time Factors | 2018 |
Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Male; Mutation; Precision Medicine; Quinolones | 2018 |
Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Combinations; Drug Interactions; Enzyme Assays; Enzyme Induction; Female; Humans; Indoles; Quinolones | 2018 |
CFTR rescue with VX-809 and VX-770 favors the repair of primary airway epithelial cell cultures from patients with class II mutations in the presence of Pseudomonas aeruginosa exoproducts.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cells, Cultured; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Exotoxins; Glycine; Humans; Hydrazines; Mutation; Pseudomonas aeruginosa; Quinolones; Regeneration; Respiratory Mucosa | 2018 |
Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; Humans; Ibuprofen; Male; Quinolones | 2018 |
Studies on articular and general toxicity of orally administered ozenoxacin in juvenile rats and dogs.
Topics: Administration, Oral; Aminopyridines; Animals; Anti-Bacterial Agents; Biomarkers; Cartilage, Articular; Dogs; Female; Humans; Joint Diseases; Male; Ofloxacin; Quinolones; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric | 2018 |
Therapeutic efficacy of ozenoxacin in animal models of dermal infection with Staphylococcus aureus.
Topics: Administration, Topical; Aminopyridines; Animals; Animals, Outbred Strains; Anti-Bacterial Agents; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Humans; Impetigo; Mice; Mupirocin; Ointments; Quinolones; Skin Cream; Staphylococcus aureus; Treatment Outcome; Wound Infection | 2018 |
A review of the antibacterial activity of ozenoxacin.
Topics: Aminopyridines; Animals; Anti-Bacterial Agents; Child; Disease Models, Animal; Dogs; Humans; Impetigo; Quinolones; Rats; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes | 2018 |
Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates.
Topics: Aminopyridines; Anti-Bacterial Agents; Humans; Impetigo; Levofloxacin; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Quinolones; Staphylococcaceae; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pyogenes | 2018 |
Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Breast Feeding; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug Monitoring; Female; Fetal Blood; Humans; Infant, Newborn; Liver Function Tests; Milk, Human; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects; Quinolones; Treatment Outcome | 2018 |
Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cell Line; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Freeze Drying; HEK293 Cells; Humans; Microscopy, Fluorescence; Mutation; Protein Stability; Quinolones; Sulfate Transporters | 2018 |
The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Drug Combinations; Female; Homozygote; Humans; Lung; Membrane Transport Modulators; Mutation; Patient Care Management; Quinolones; Respiratory Function Tests; Symptom Flare Up; Treatment Outcome | 2018 |
Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug Therapy, Combination; HEK293 Cells; Humans; Mutation; Quinolones | 2018 |
Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Blood Glucose; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA; Drug Combinations; Female; Forced Expiratory Volume; Glucose Tolerance Test; Glycated Hemoglobin; Homozygote; Humans; Male; Mutation; Prognosis; Quinolones; Treatment Outcome | 2019 |
Prolonged co-treatment with HGF sustains epithelial integrity and improves pharmacological rescue of Phe508del-CFTR.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cell Line; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Hepatocyte Growth Factor; Humans; Models, Biological; Mutant Proteins; Quinolones; Treatment Outcome | 2018 |
Rate and predictors of prescription of lumacaftor - Ivacaftor in the 18 months following approval in the United States.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Drug Combinations; Drug Prescriptions; Eligibility Determination; Female; Humans; Insurance Claim Review; Male; Product Surveillance, Postmarketing; Quinolones; Registries; Severity of Illness Index; United States | 2018 |
False-positive cannabinoid screens in adult cystic fibrosis patients treated with lumacaftor/ivacaftor.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Cannabinoids; Chloride Channel Agonists; Cystic Fibrosis; Diagnostic Errors; Drug Combinations; False Positive Reactions; Female; Humans; Male; Middle Aged; Quinolones; Substance Abuse Detection | 2018 |
Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Budgets; Clinical Decision-Making; Cost-Benefit Analysis; Cystic Fibrosis; Decision Support Techniques; Drug Combinations; Drug Costs; Forced Expiratory Volume; Humans; Lung; Models, Economic; Quality-Adjusted Life Years; Quinolones; Respiratory System Agents; Time Factors; Treatment Outcome | 2018 |
Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Child; Cost-Benefit Analysis; Cystic Fibrosis; Female; Humans; Male; Quality-Adjusted Life Years; Quinolones; United States | 2018 |
The cystic fibrosis airway milieu enhances rescue of F508del in a pre-clinical model.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Bronchi; Cell Line; Colforsin; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelial Cells; Humans; Inflammation; Mutation; Quinolones; Respiratory System | 2018 |
Cystic Fibrosis: Emerging Understanding and Therapies.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chronic Disease; Combined Modality Therapy; Comprehension; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Management; Disease Progression; Drug Approval; Female; Genetic Predisposition to Disease; Humans; Lung Transplantation; Male; Prognosis; Quinolones; Risk Assessment; Severity of Illness Index; Survival Analysis; United States; United States Food and Drug Administration | 2019 |
Tezacaftor/Ivacaftor (Symdeko) for cystic fibrosis.
Topics: Administration, Oral; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Administration Schedule; Drug Combinations; Drug Interactions; Humans; Indoles; Lung; Membrane Transport Modulators; Mutation; Quinolones; Treatment Outcome | 2018 |
Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Animals; Benzodioxoles; Chloride Channel Agonists; CHO Cells; Cricetulus; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Ion Channel Gating; Mutation; Protein Conformation; Quinolones | 2019 |
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Case-Control Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Cytokines; Drug Combinations; Female; Humans; Ion Transport; Macrophages; Male; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Signal Transduction | 2018 |
Compassionate Use of Lumacaftor/Ivacaftor in Cystic Fibrosis: Spanish Experience.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chloride Channel Agonists; Compassionate Use Trials; Cystic Fibrosis; Drug Combinations; Female; Humans; Male; Middle Aged; Quinolones; Retrospective Studies; Spain; Young Adult | 2018 |
Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation.
Topics: Adrenal Cortex Hormones; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Forced Expiratory Volume; Gene Deletion; Homozygote; Humans; Leukocytes; Logistic Models; Male; Medication Adherence; Quinolones; Receptors, Interleukin-8B; Tetraspanin 30 | 2018 |
Predictive factors for lumacaftor/ivacaftor clinical response.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Biomarkers, Pharmacological; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug Monitoring; Female; Humans; Male; Mutation; Pharmacogenomic Testing; Quinolones; Respiratory Function Tests; Sweat; Treatment Outcome; Young Adult | 2019 |
Folding-function relationship of the most common cystic fibrosis-causing CFTR conductance mutants.
Topics: Alleles; Aminophenols; Aminopyridines; Benzodioxoles; Biopsy; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genotype; HEK293 Cells; Humans; Mutation; Organoids; Protein Folding; Protein Structure, Tertiary; Quinolones; Rectum; Transfection | 2019 |
New Drugs 2019, part 1.
Topics: Aminophenols; Aminopyridines; Antibodies, Monoclonal, Humanized; Benzoates; Benzodioxoles; beta-Alanine; Bridged Bicyclo Compounds, Heterocyclic; cis-trans-Isomerases; Drug Approval; Drug Combinations; Glucagon-Like Peptides; Humans; Indoles; Quinolones; United States; United States Food and Drug Administration | 2019 |
Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers.
Topics: Administration, Inhalation; Aminophenols; Aminopyridines; Animals; Benzodioxoles; Cell Line; Chloride Channel Agonists; Cystic Fibrosis; Drug Carriers; Drug Combinations; Humans; Lipids; Lung; Mice, Transgenic; Nanostructures; Quinolones | 2019 |
The study of CFTR modulators in the very young.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Quinolones | 2019 |
Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.
Topics: Alleles; Aminophenols; Aminopyridines; Antiporters; Base Sequence; Benzodioxoles; Body Mass Index; Case-Control Studies; Cellular Reprogramming; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Diffusion Chambers, Culture; Epithelial Cells; Gene Expression; Genotype; Humans; Models, Biological; Nasal Mucosa; Polymorphism, Single Nucleotide; Primary Cell Culture; Quinolones; Sequence Deletion; Sulfate Transporters; Sweat | 2019 |
From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2.
Topics: Adult; Aminophenols; Aminopyridines; Anti-Arrhythmia Agents; Benzodioxoles; Drug Combinations; Electrocardiography; Female; Humans; Induced Pluripotent Stem Cells; Long QT Syndrome; Precision Medicine; Quinolones | 2019 |
Exhaled nitric oxide in stable adult cystic fibrosis patients, during exacerbation and following CFTR-modifying treatment.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Breath Tests; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Drug Combinations; Exhalation; Female; Humans; Male; Nitric Oxide; Prospective Studies; Quinolones; Young Adult | 2019 |
Effects of Lumacaftor/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis.
Topics: Activities of Daily Living; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug Monitoring; Exercise; Exercise Tolerance; Forced Expiratory Volume; Humans; Male; Middle Aged; Mutation; Oxygen Consumption; Quinolones; Treatment Outcome | 2019 |
Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR.
Topics: Adenosine Triphosphate; Aminophenols; Aminopyridines; Animals; Base Sequence; Benzodioxoles; Chloride Channel Agonists; CHO Cells; Colforsin; Cricetulus; Cyclic AMP-Dependent Protein Kinases; Cystic Fibrosis Transmembrane Conductance Regulator; Gene Expression; Genistein; Ion Transport; Mice; NIH 3T3 Cells; Patch-Clamp Techniques; Protein Stability; Quinolones; Sequence Deletion; Species Specificity; Temperature; Transgenes | 2019 |
Phenotyping ciliary dynamics and coordination in response to CFTR-modulators in Cystic Fibrosis respiratory epithelial cells.
Topics: Algorithms; Aminophenols; Aminopyridines; Benzodioxoles; Bronchi; Cilia; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Epithelial Cells; Genotype; Humans; Microscopy; Oscillometry; Phenotype; Quinolones; Video Recording | 2019 |
Impact of CFTR-modulating drugs on GH-IGF-1 axis impairment in adult patients with cystic fibrosis.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Follow-Up Studies; Growth Disorders; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Mutation; Prognosis; Quinolones | 2019 |
Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Retrospective Studies; Staphylococcal Infections; Staphylococcus aureus; Young Adult | 2019 |
Impact of Phosphodiesterase 4 Inhibition on the Operational Efficacy, Response Maxima, and Kinetics of Indacaterol-Induced Gene Expression Changes in BEAS-2B Airway Epithelial Cells: A Global Transcriptomic Analysis.
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Aminoquinolines; Benzamides; Cell Line; Cyclopropanes; Drug Synergism; Epithelial Cells; Gene Expression Profiling; Gene Expression Regulation; Humans; Indans; Lung; Oligonucleotide Array Sequence Analysis; Phosphodiesterase 4 Inhibitors; Quinolones; Salmeterol Xinafoate; Sulfones | 2019 |
Microbiological profile of ozenoxacin.
Topics: Aminopyridines; Anti-Bacterial Agents; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones | 2019 |
Unexpected analytical interference in isavuconazole UV determination in a child in therapy with lumacaftor/ivacaftor for cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Cystic Fibrosis; Female; Humans; Male; Nitriles; Pyridines; Quinolones; Triazoles | 2019 |
Ozenoxacin 1% cream (Xepi) for impetigo.
Topics: Administration, Cutaneous; Aminopyridines; Anti-Bacterial Agents; Humans; Impetigo; Quinolones; Skin Cream | 2019 |
Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction.
Topics: Adult; Aminophenols; Aminopyridines; Australia; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Exercise Tolerance; Female; Genotype; Homozygote; Humans; Male; Middle Aged; Mutation; Quinolones; Respiratory Function Tests; Walk Test; Young Adult | 2019 |
Negotiations between the NHS and Vertex on access to lumacaftor and ivacaftor become protracted.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Drug Combinations; Drug Industry; England; Humans; Negotiating; Quinolones; State Medicine | 2019 |
Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Genotype; Humans; Lung; Mutation; Pregnancy; Pregnancy Outcome; Quinolones | 2019 |
Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Child; Cross-Sectional Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Forced Expiratory Volume; Humans; Internationality; Male; Multivariate Analysis; Mutation; Patient Reported Outcome Measures; Quality of Life; Quinolones; Regression Analysis; Surveys and Questionnaires | 2019 |
ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channe
Topics: Aminophenols; Aminopyridines; Animals; Arginase; Arginine; Benzodioxoles; Bronchi; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Cytosol; Drug Combinations; Humans; Intestinal Mucosa; Mice; Mutation; Nitric Oxide; Nose; Quinolones | 2019 |
Effect of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Humans; Lung; Male; Medicaid; Middle Aged; Mutation; Quinolones; United States; Young Adult | 2019 |
Whole-blood transcriptomic responses to lumacaftor/ivacaftor therapy in cystic fibrosis.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Biomarkers; Biomarkers, Pharmacological; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Homozygote; Humans; Ion Transport; Male; Metabolomics; Mutation; Pharmacogenomic Testing; Pharmacogenomic Variants; Prognosis; Quinolones; Transcriptome | 2020 |
Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis.
Topics: Aminopyridines; Anti-Bacterial Agents; Bacterial Proteins; DNA Gyrase; Drug Resistance, Bacterial; Methicillin-Resistant Staphylococcus aureus; Mutation; Quinolones; Staphylococcus epidermidis | 2019 |
Cystic fibrosis transmembrane conductance regulator modulators reduce the risk of recurrent acute pancreatitis among adult patients with pancreas sufficient cystic fibrosis.
Topics: Adult; Aged; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Exocrine Pancreatic Insufficiency; Female; Humans; Indoles; Male; Middle Aged; Quinolones; Retrospective Studies | 2019 |
Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cost-Benefit Analysis; Cystic Fibrosis; Drug Combinations; Drug Costs; Humans; Orphan Drug Production; Quinolones | 2019 |
Combination Therapy with Lumacaftor-Ivacaftor in Cystic Fibrosis. Keeping It Real.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Humans; Quinolones | 2020 |
Longitudinal changes in lung function following initiation of lumacaftor/ivacaftor combination.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug Monitoring; Duration of Therapy; Female; Forced Expiratory Volume; Humans; Longitudinal Studies; Male; Medication Therapy Management; Quinolones; Respiratory Function Tests; Retrospective Studies; Treatment Outcome; United States | 2020 |
Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease.
Topics: Administration, Intravenous; Adult; Aminophenols; Aminopyridines; Anti-Bacterial Agents; Australia; Benzodioxoles; Case-Control Studies; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Forced Expiratory Volume; Humans; Male; Mutation; Quinolones; Respiratory Function Tests; Respiratory Tract Infections; Symptom Flare Up | 2020 |
Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France.
Topics: Adult; Age Factors; Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cost-Benefit Analysis; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Forced Expiratory Volume; France; Homozygote; Humans; Male; Medication Adherence; Quinolones; Respiratory Function Tests; Retrospective Studies; Treatment Outcome | 2020 |
Anti-inflammatory effects of ozenoxacin, a topical quinolone antimicrobial agent.
Topics: Acne Vulgaris; Aminopyridines; Animals; Anti-Inflammatory Agents; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Inflammation; Interleukin-6; Interleukin-8; Male; Propionibacterium acnes; Quinolones; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 2020 |
Unmasking catamenial hemoptysis in the era of CFTR modulator therapy.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Bronchoscopy; Chloride Channel Agonists; Cystic Fibrosis; Drug Combinations; Drug Therapy, Combination; Endometriosis; Female; Fertility Agents, Female; Hemoptysis; Humans; Indoles; Leuprolide; Pyrazoles; Pyridines; Quinolines; Quinolones; Radiography, Thoracic; Thoracic Diseases; Tomography, X-Ray Computed | 2020 |
Precise Targeting of miRNA Sites Restores CFTR Activity in CF Bronchial Epithelial Cells.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Bronchi; Cells, Cultured; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug Synergism; Epithelial Cells; Female; Humans; Indoles; Infant; Male; MicroRNAs; Middle Aged; Models, Biological; Nanoparticles; Oligonucleotides; Polylactic Acid-Polyglycolic Acid Copolymer; Quinolones | 2020 |
Anti-Infectives Restore ORKAMBI
Topics: Aminophenols; Aminopyridines; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Benzodioxoles; Bronchi; Cell Line; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Tobramycin | 2020 |
Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Cytokines; Down-Regulation; Drug Therapy, Combination; Female; Humans; Indoles; Inflammation; Interleukin-18; Interleukin-1beta; Male; Monocytes; Quinolones; Tumor Necrosis Factor-alpha; Young Adult | 2020 |
Genomically-guided therapies: A new era for cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Genetic Therapy; Humans; Indoles; Mutation; Precision Medicine; Quinolones; Respiratory System Agents | 2020 |
Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Blood Glucose; Child; Cystic Fibrosis; Diabetes Mellitus; Drug Administration Schedule; Drug Combinations; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Male; Middle Aged; Prospective Studies; Quinolones; Young Adult | 2020 |
Structural Consequences of the 1,2,3-Triazole as an Amide Bioisostere in Analogues of the Cystic Fibrosis Drugs VX-809 and VX-770.
Topics: Amides; Aminophenols; Aminopyridines; Benzodioxoles; Crystallography, X-Ray; Cystic Fibrosis; Humans; Models, Molecular; Molecular Structure; Quantum Theory; Quinolones; Triazoles | 2020 |
Can lumacaftor-ivacaftor reverse glucose-tolerance abnormalities in cystic fibrosis?
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Glucose; Humans; Quinolones | 2020 |
Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Body Mass Index; Child; Chlorides; Correlation of Data; Cystic Fibrosis; Drug Combinations; Female; Forced Expiratory Volume; Humans; Male; Quinolones; Retrospective Studies; Sex Factors; Sweat; Young Adult | 2021 |
Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Child, Preschool; Chloride Channel Agonists; Cross-Sectional Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Humans; Indoles; Infant; Male; Mutation; Pyrazoles; Pyridines; Quinolines; Quinolones; Registries; Turkey; Young Adult | 2020 |
Comment on "Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients".
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Glucose; Humans; Quinolones | 2020 |
Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Male; Middle Aged; Mutation; Quinolones; Respiratory Function Tests; United States | 2020 |
Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4
Topics: Aminophenols; Aminopyridines; Benzodioxoles; CD4-Positive T-Lymphocytes; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug Hypersensitivity; Female; Humans; Quinolones; Young Adult | 2021 |
Accumulation and persistence of ivacaftor in airway epithelia with prolonged treatment.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Bronchi; Cell Culture Techniques; Chloride Channel Agonists; Cystic Fibrosis; Drug Combinations; Epithelial Cells; Humans; Indoles; Quinolones; Respiratory Mucosa | 2020 |
Lumacaftor/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Cholesterol; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Humans; Liver; Male; Mutation; Quinolones; Treatment Outcome; Young Adult | 2021 |
Survey of patients with cystic fibrosis and caregivers decisions regarding CFTR modulators.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Caregivers; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug Substitution; Foundations; Humans; Indoles; Middle Aged; Quinolones; Social Media; Surveys and Questionnaires; Young Adult | 2020 |
Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Indoles; Male; Mutation; Pancreas; Pancreatic Cyst; Quinolones; Treatment Outcome; Ultrasonography | 2020 |
Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Disease Progression; Drug Combinations; Female; France; Humans; Male; Quinolones; Respiratory Function Tests | 2021 |
GM1 as Adjuvant of Innovative Therapies for Cystic Fibrosis Disease.
Topics: Adjuvants, Immunologic; Aminophenols; Aminopyridines; Benzodioxoles; Bronchi; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelial Cells; G(M1) Ganglioside; Humans; Mutation; Quinolones; Therapies, Investigational | 2020 |
Evidence of Small Airways Disease and the Immediate Effects of Lumacaftor/Ivacaftor in Children with Cystic Fibrosis.
Topics: Adolescent; Airway Remodeling; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Drug Combinations; Female; Forced Expiratory Volume; Humans; Male; Negative Results; Pulmonary Disease, Chronic Obstructive; Quinolones; Retrospective Studies; Risk Factors | 2020 |
Altered iron metabolism in cystic fibrosis macrophages: the impact of CFTR modulators and implications for Pseudomonas aeruginosa survival.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Biofilms; Child; Culture Media, Conditioned; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Gene Expression Profiling; Host-Pathogen Interactions; Humans; Iron; Iron-Regulatory Proteins; Macrophages; Male; Middle Aged; Pseudomonas aeruginosa; Quinolones; Sputum | 2020 |
Full Rescue of F508del-CFTR Processing and Function by CFTR Modulators Can Be Achieved by Removal of Two Regulatory Regions.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cell Line; Cell Membrane; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Mutation; Protein Domains; Quinolones; Regulatory Sequences, Nucleic Acid; Signal Transduction | 2020 |
Phosphorylation of the Chaperone-Like HspB5 Rescues Trafficking and Function of F508del-CFTR.
Topics: Aminophenols; Aminopyridines; Animals; Benzodioxoles; Cell Line; Cell Membrane; Crystallins; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Heat-Shock Proteins; HEK293 Cells; Humans; Male; Mice; Molecular Chaperones; Mutation; Phenylalanine; Phosphorylation; Proteasome Endopeptidase Complex; Protein Transport; Quinolones | 2020 |
Comparative activity of ozenoxacin and other quinolones in Staphylococcus aureus strains overexpressing the efflux pump-encoding genes mepA and norA.
Topics: Aminopyridines; Anti-Bacterial Agents; Bacterial Proteins; Endopeptidases; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Quinolones; Reserpine; Staphylococcus aureus | 2020 |
Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Bronchi; Cells, Cultured; Ceramides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Epithelial Cells; Humans; Indoles; Lipid Metabolism; Lipidomics; Pyrazoles; Pyridines; Quinolines; Quinolones; Spectrometry, Mass, Electrospray Ionization | 2020 |
CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cells, Cultured; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Indoles; Mutant Proteins; Mutation, Missense; Pyrazoles; Pyridines; Pyrrolidines; Quinolones | 2021 |
Ivacaftor or lumacaftor/ivacaftor treatment does not alter the core CF airway epithelial gene response to rhinovirus.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cells, Cultured; Common Cold; Cystic Fibrosis; Drug Combinations; Humans; Quinolones; Respiratory Mucosa; Rhinovirus | 2021 |
Comparison of Organoid Swelling and
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chlorides; Colforsin; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Edema; Female; Forced Expiratory Volume; Homozygote; Humans; In Vitro Techniques; Male; Membrane Potentials; Middle Aged; Nasal Mucosa; Organoids; Precision Medicine; Prospective Studies; Quinolones; Rectum; Sweat; Treatment Outcome; Vital Capacity; Young Adult | 2020 |
Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: The case of S955P and 1717-2A>G.
Topics: Alleles; Aminophenols; Aminopyridines; Benzodioxoles; Blotting, Western; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Electrophysiology; Fluorescent Antibody Technique; Genotype; Humans; Indoles; Mutation; Precision Medicine; Quinolones | 2020 |
Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Inflammation; Lung; Mutation; Quinolones | 2020 |
Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug Evaluation, Preclinical; Drug Resistance; Humans; Mutation; Quinolones | 2021 |
Drug efficacy and toxicity prediction: an innovative application of transcriptomic data.
Topics: Aminophenols; Aminopyridines; Animals; Antineoplastic Agents; Benzodioxoles; Cell Death; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Combinations; Drug Development; Epithelial Cells; Gene Expression Profiling; Gene Regulatory Networks; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyrazoles; Quinolones; Toxicity Tests; Transcriptome | 2020 |
Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Glucose Tolerance Test; Homozygote; Humans; Insulin Secretion; Longitudinal Studies; Male; Middle Aged; Mutation; Quinolones | 2021 |
Urinary Exosomes of Patients with Cystic Fibrosis Unravel CFTR-Related Renal Disease.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Case-Control Studies; Child; Child, Preschool; Cystic Fibrosis; Drug Combinations; Exosomes; Humans; Indoles; Kidney Diseases; Proteome; Quinolones; Young Adult | 2020 |
Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chromatography, Liquid; Cystic Fibrosis; Drug Combinations; Humans; Indoles; Mutation; Plasma; Quinolones; Sputum; Tandem Mass Spectrometry | 2021 |
Targeted deubiquitination rescues distinct trafficking-deficient ion channelopathies.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Channelopathies; Cystic Fibrosis; Deubiquitinating Enzymes; Drug Combinations; Humans; Indoles; Ion Transport; Long QT Syndrome; Myocytes, Cardiac; Nedd4 Ubiquitin Protein Ligases; Potassium Channels; Pyrazoles; Pyridines; Quinolines; Quinolones | 2020 |
The PROSPECT Is Bright for CFTR Modulators.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Quinolones; Treatment Outcome | 2021 |
Tribulations and (clinical) trials in cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cannabinoid Receptor Agonists; Chloride Channel Agonists; Clinical Trials as Topic; Cystic Fibrosis; Dronabinol; Drug Combinations; Humans; Indoles; Quinolones | 2021 |
The march towards CFTR modulator access for all people with CF: The end of the beginning.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Indoles; Mutation; Precision Medicine; Pyrazoles; Pyridines; Pyrrolidines; Quinolones | 2021 |
The effectiveness and value of novel treatments for cystic fibrosis.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chloride Channel Agonists; Cost-Benefit Analysis; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Approval; Drug Combinations; Drug Costs; Health Policy; Humans; Indoles; Models, Economic; Mutation; Pyrazoles; Pyridines; Quinolines; Quinolones; Treatment Outcome; United States; United States Food and Drug Administration | 2021 |
Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study.
Topics: Adolescent; Adult; Aged; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chloride Channel Agonists; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Humans; Male; Middle Aged; Prospective Studies; Quinolones; Sweat | 2021 |
Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Blood Glucose; Case-Control Studies; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Follow-Up Studies; Homozygote; Humans; Insulin Secretion; Male; Mutation; Prognosis; Quinolones; Retrospective Studies; Young Adult | 2021 |
Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.
Topics: Aminophenols; Aminopyridines; Animals; Benzoates; Benzodioxoles; Benzopyrans; Cell Line; Chlorides; Codon, Nonsense; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelial Cells; Humans; Ion Transport; Protein Biosynthesis; Pyrans; Pyrazoles; Quinolones; Rats; Recovery of Function; Thyroid Epithelial Cells | 2021 |
[Cystic fibrosis prognosis in Europa : chronicle of an announced dilemma].
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Europe; Humans; Mutation; Prognosis; Quinolones | 2021 |
Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cells, Cultured; Child, Preschool; Chloride Channel Agonists; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelial Cells; Female; Genotype; Humans; Mutation, Missense; Nasal Mucosa; Pancreatic Elastase; Quinolones | 2021 |
In vitro activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD 2007-18).
Topics: Aminopyridines; Anti-Bacterial Agents; Canada; Fusidic Acid; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mupirocin; Quinolones; Soft Tissue Infections; Staphylococcal Infections; Staphylococcus aureus | 2021 |
Optical Measurements of Sweat for in Vivo Quantification of CFTR Function in Individual Sweat Glands.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Optics and Photonics; Quinolones; Sweat; Sweat Glands | 2021 |
Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Mutation; Quinolones | 2021 |
Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chloride Channel Agonists; Cohort Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Female; Humans; Longitudinal Studies; Male; Middle Aged; Mucociliary Clearance; Prospective Studies; Quinolones; Young Adult | 2022 |
Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosis.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cohort Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Quinolones; Respiratory Function Tests | 2022 |
Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Biomarkers; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Liver; Mutation; Prospective Studies; Quinolones | 2022 |
Restoration of exocrine pancreatic function in child with lumacaftor/ivacaftor therapy in cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Quinolones | 2022 |
Mislocalization of CFTR expression in acute pancreatitis and the beneficial effect of VX-661 + VX-770 treatment on disease severity.
Topics: Acute Disease; Aminophenols; Aminopyridines; Animals; Benzodioxoles; Cystic Fibrosis Transmembrane Conductance Regulator; Indoles; Mice; Mutation; Pancreatitis; Quinolones; Severity of Illness Index | 2021 |
Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chromatography, Liquid; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Indoles; Isotopes; Mutation; Pyrazoles; Pyridines; Pyrrolidines; Quinolones; Tandem Mass Spectrometry | 2022 |
Liquid chromatography-mass spectrometric methods for trace quantification of potential genotoxic impurities in ivacaftor and lumacaftor.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Boronic Acids; Chromatography, High Pressure Liquid; Chromatography, Liquid; DNA Damage; Nitrophenols; Quinolones; Reproducibility of Results | 2022 |
Radiomics-derived morphological features predict pulmonary function response during lumacaftor/ivacaftor therapy in patients with cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Drug Combinations; Humans; Quinolones; Tomography, X-Ray Computed; Unsupervised Machine Learning | 2022 |
Diversity of approaches in artificial intelligence: an opportunity for discoveries in thoracic imaging.
Topics: Aminophenols; Aminopyridines; Artificial Intelligence; Benzodioxoles; Cystic Fibrosis; Humans; Quinolones; Tomography, X-Ray Computed; Unsupervised Machine Learning | 2022 |
Proximity Profiling of the CFTR Interaction Landscape in Response to Orkambi.
Topics: Adaptor Proteins, Signal Transducing; Aminophenols; Aminopyridines; Benzodioxoles; Chlorides; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; HEK293 Cells; Humans; Mass Spectrometry; Mutation; Protein Interaction Maps; Quinolones; Vesicular Transport Proteins | 2022 |
Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as Potent c-Myc G-Quadruplex Stabilizers to Suppress c-Myc Transcription and Myeloma Growth.
Topics: Aminopyridines; DNA; Fluoroquinolones; Humans; Indans; Molecular Docking Simulation; Multiple Myeloma; Naphthyridines; Oxadiazoles; Quinolones; RNA, Messenger | 2022 |
Changes in Glucose Breath Test in Cystic Fibrosis Patients Treated With 1 Month of Lumacaftor/Ivacaftor.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Breath Tests; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Glucose; Humans; Hydrogen; Longitudinal Studies; Male; Mutation; Quinolones; Young Adult | 2022 |
Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor.
Topics: Aminophenols; Aminopyridines; Bacterial Toxins; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Denmark; Drug Combinations; Exercise Test; Exercise Tolerance; Humans; Indoles; Mutation; Prospective Studies; Quinolones | 2022 |
T-cell-mediated hypersensitivity to lumacaftor and ivacaftor in cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Drug Combinations; Humans; Mutation; Quinolones; T-Lymphocytes | 2022 |
Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Humans; Mutation; Pneumonia; Quinolones | 2022 |
Antimicrobial activity of ozenoxacin and other antimicrobials against Staphylococcus aureus strains isolated from clinical skin specimens in Japan in 2019 and 2020.
Topics: Aminopyridines; Anti-Bacterial Agents; Anti-Infective Agents; Gentamicins; Humans; Japan; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Quinolones; Staphylococcal Infections; Staphylococcus aureus | 2022 |